Document and Entity Information
Document and Entity Information - shares | 3 Months Ended | |
Mar. 31, 2020 | Jul. 23, 2021 | |
Cover [Abstract] | ||
Entity Registrant Name | NUTRA PHARMA CORP | |
Entity Central Index Key | 0001119643 | |
Document Type | 10-Q | |
Document Period End Date | Mar. 31, 2020 | |
Amendment Flag | false | |
Current Fiscal Year End Date | --12-31 | |
Entity Current Reporting Status | No | |
Entity Interactive Data Current | No | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 7,267,619,714 | |
Document Fiscal Period Focus | Q1 | |
Document Fiscal Year Focus | 2020 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets - USD ($) | Mar. 31, 2020 | Dec. 31, 2019 |
Current assets: | ||
Cash | ||
Accounts receivable | 33,581 | 32,479 |
Inventory, current portion | 6,624 | 8,177 |
Prepaid expenses and other current assets | 21,265 | 17,150 |
Total current assets | 61,470 | 57,806 |
Inventory, less current portion | 65,568 | 52,183 |
Property and equipment, net | 6,051 | 6,763 |
Operating lease right-of-use assets | 200,276 | 207,530 |
Security deposit | 15,550 | 15,550 |
Total assets | 348,915 | 339,832 |
Current liabilities: | ||
Accounts payable | 570,239 | 583,226 |
Accrued expenses | 630,274 | 612,547 |
Accrued payroll due to officers | 1,296,893 | 1,249,393 |
Accrued interest to related parties | 164,276 | 159,555 |
Due to officer | 199,290 | 122,812 |
Derivative liabilities | 1,146,521 | 835,868 |
Other debt, net of discount, current portion | 4,844,952 | 7,352,954 |
Operating lease obligations, current portion | 75,588 | 73,278 |
Total current liabilities | 8,928,033 | 10,989,633 |
Convertible note, less current portion | 225,597 | 907,912 |
Operating lease obligations, less current portion | 123,576 | 143,322 |
Total liabilities | 9,277,206 | 12,040,867 |
Commitments and Contingencies | ||
Stockholders' deficit: | ||
Preferred stock, $0.001 par value, 20,000,000 shares authorized: 3,000,000 Series A Preferred shares issued and outstanding at March 31, 2019 and December 31, 2019 | 3,000 | 3,000 |
Common stock, $0.001 par value, 8,000,000,000 shares authorized: 6,622,746,111 and 5,876,746,111 shares issued and outstanding at March 31, 2020 and December 31, 2019 | 6,622,746 | 5,876,746 |
Additional paid-in capital | 50,127,203 | 50,283,503 |
Accumulated deficit | (65,681,240) | (67,864,284) |
Total stockholders' deficit | (8,928,291) | (11,701,035) |
Total liabilities and stockholders' deficit | $ 348,915 | $ 339,832 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares | Mar. 31, 2020 | Dec. 31, 2019 |
Preferred stock, par value | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized | 20,000,000 | 20,000,000 |
Common stock, par value | $ 0.001 | $ 0.001 |
Common stock, shares authorized | 8,000,000,000 | 8,000,000,000 |
Common stock, shares issued | 6,622,746,111 | 5,876,746,111 |
Common stock, shares outstanding | 6,622,746,111 | 5,876,746,111 |
Series A Preferred Stock [Member] | ||
Preferred stock, shares issued | 3,000,000 | 3,000,000 |
Preferred stock, shares outstanding | 3,000,000 | 3,000,000 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | ||
Mar. 31, 2020 | Mar. 31, 2019 | ||
Income Statement [Abstract] | |||
Net sales | $ 17,116 | $ 41,322 | |
Cost of sales | (5,279) | (15,625) | |
Gross profit | 11,837 | 25,697 | |
Operating expenses: | |||
Selling, general and administrative - including stock based compensation of $7,500 and $30,000, respectively | 241,441 | 274,635 | |
Bad debt recovery - related party | (39,500) | ||
Total operating expenses | 201,941 | 274,635 | |
Loss from operations | (190,104) | (248,938) | |
Other income (expenses) | |||
Rental Income | 3,000 | ||
Interest expense | (68,873) | (75,145) | |
Interest expense to related parties | (4,721) | (4,196) | |
Change in fair value of convertible notes and derivatives | 2,542,942 | (129,417) | |
Stock issued for loan modification | (77,200) | ||
Gain (loss) on settlement of debt and accrued expense, net | (22,000) | 57,253 | |
Total other income (expenses) | 2,373,148 | (151,505) | |
Income (loss) before income taxes | 2,183,044 | (400,443) | |
Provision for income taxes | |||
Net income (loss) | $ 2,183,044 | $ (400,443) | |
Net income (loss) per share - basic and diluted | $ 0 | $ 0 | |
Weighted average number of shares outstanding during the period - basic | 6,272,328,529 | 4,112,446,110 | |
Weighted average number of shares outstanding during the period - diluted | [1] | 12,293,204,022 | 4,112,446,110 |
[1] | Includes potential common shares that are in excess of authorized shares. |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Operations (Parenthetical) - USD ($) | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Income Statement [Abstract] | ||
Stock based compensation | $ 7,500 | $ 30,000 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Changes in Stockholders' Deficit (Unaudited) - USD ($) | Preferred Stock [Member] | Common Stock [Member] | Additional Paid-In Capital [Member] | Accumulated Deficit [Member] | Total |
Balance at Dec. 31, 2018 | $ 3,000 | $ 4,046,746 | $ 51,286,503 | $ (61,272,842) | $ (5,936,593) |
Balance, shares at Dec. 31, 2018 | 3,000,000 | 4,046,746,110 | |||
Common stock issued for settlement of debt | $ 81,000 | (48,600) | 32,400 | ||
Common stock issued for settlement of debt, shares | 81,000,000 | ||||
Warrants issued with Debt--Debt discount | 8,147 | 8,147 | |||
Net income loss | (400,443) | (400,443) | |||
Balance at Mar. 31, 2019 | $ 3,000 | $ 4,127,746 | 51,246,050 | (61,673,285) | (6,296,489) |
Balance, shares at Mar. 31, 2019 | 3,000,000 | 4,127,746,110 | |||
Balance at Dec. 31, 2019 | $ 3,000 | $ 5,876,746 | 50,283,503 | (67,864,284) | (11,701,035) |
Balance, shares at Dec. 31, 2019 | 3,000,000 | 5,876,746,111 | |||
Common stock issued for debt modification and penalty | $ 121,000 | (43,800) | 77,200 | ||
Common stock issued for debt modification and penalty, shares | 121,000,000 | ||||
Common stock issued for conversion of debt | $ 500,000 | (75,000) | 425,000 | ||
Common stock issued for conversion of debt, shares | 500,000,000 | ||||
Common stock issued for settlement of debt | $ 125,000 | (37,500) | 87,500 | ||
Common stock issued for settlement of debt, shares | 125,000,000 | ||||
Net income loss | 2,183,044 | 2,183,044 | |||
Balance at Mar. 31, 2020 | $ 3,000 | $ 6,622,746 | $ 50,127,203 | $ (65,681,240) | $ (8,928,291) |
Balance, shares at Mar. 31, 2020 | 3,000,000 | 6,622,746,111 |
Condensed Consolidated Statem_4
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | Dec. 31, 2019 | |
Cash flows from operating activities: | |||
Net income (loss) | $ 2,183,044 | $ (400,443) | |
Adjustments to reconcile net income (loss) to net cash used in operating activities: | |||
Bad debt expense | 2,789 | ||
Bad debt recovery - related party | (39,500) | ||
Accrued interest expense for amount due to officer | 1,678 | 1,817 | |
(Gain) loss on settlement of debt and accrued expense | 22,000 | (57,253) | |
Depreciation | 712 | 1,105 | $ 1,105 |
Stock-based compensation | 7,500 | 30,000 | |
Stock-based loan modification cost | 77,200 | ||
Change in fair value of convertible notes and derivatives | (2,542,942) | 129,417 | |
Amortization of loan discount | 24,873 | 38,117 | |
Amortization of operating lease right-of-use assets | 7,254 | 15,244 | |
Changes in operating assets and liabilities: | |||
Increase in accounts receivable | (1,102) | (13,723) | |
Increase in inventory | (11,832) | (1,282) | |
Increase(decrease) in prepaid expenses and other current assets | (11,615) | 4,152 | |
Increase(decrease) in accounts payable | (12,987) | 65,014 | |
Increase in accrued expenses | 45,377 | 45,287 | |
Increase in accrued payroll due to officers | 47,500 | 59,400 | |
Increase in accrued interest to related parties | 4,721 | 4,196 | |
Decrease in operating lease obligations | (17,436) | (15,341) | |
Net cash used in operating activities | (215,555) | (91,504) | |
Cash flows from financing activities: | |||
Loans from officer | 118,500 | 4,100 | |
Repayment of officer loans | (4,200) | (9,950) | |
Proceeds from convertible notes | 107,926 | 100,508 | |
Advances from an unrelated third party | 25,000 | ||
Repayments of other notes payable | (31,671) | (3,154) | |
Net cash provided by financing activities | 215,555 | 91,504 | |
Net increase in cash | |||
Cash - beginning of period | |||
Cash - end of period | |||
Supplemental Cash Flow Information: | |||
Cash paid for interest | 500 | ||
Cash paid for income taxes | |||
Non Cash Financing and Investing: | |||
Stocks issued in settlement of notes, accounts payable, and accrued expenses | 87,500 | 32,400 | |
Shares issued for conversion of debt | 425,000 | ||
Warrants issued with Debt--Debt discount | 8,147 | ||
Right-of-use asset due to adoption of ASC 842 | 281,175 | ||
Operating lease liabilities due to adoption of ASC 842 | 281,175 | ||
Reclassification of accrued interest to debt | $ 12,150 |
Basis of Presentation and Summa
Basis of Presentation and Summary of Significant Accounting Policies | 3 Months Ended |
Mar. 31, 2020 | |
Accounting Policies [Abstract] | |
Basis of Presentation and Summary of Significant Accounting Policies | 1. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Organization Nutra Pharma Corp. (“Nutra Pharma”), is a holding company that owns intellectual property and operates in the biotechnology industry. Nutra Pharma was incorporated under the laws of the state of California on February 1, 2000, under the original name of Exotic-Bird.com. Through its wholly-owned subsidiary, ReceptoPharm, Inc. (“ReceptoPharm”), Nutra Pharma conducts drug discovery research and development activities. In October 2009, Nutra Pharma launched its first consumer product called Cobroxin ® ® ® Basis of Presentation and Consolidation The Unaudited Condensed Consolidated Financial Statements and notes are presented in accordance with the rules and regulations of the Securities and Exchange Commission and do not contain certain information included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019. In the opinion of management, all adjustments considered necessary for a fair presentation have been included and are of a normal, recurring nature. Interim results are not necessarily indicative of results for a full year. Therefore, the interim Unaudited Condensed Consolidated Financial Statements should be read in conjunction with the Consolidated Financial Statements and notes thereto contained in the Company’s Annual Report on Form 10-K. The accompanying Unaudited Condensed Consolidated Financial Statements include the results of Nutra Pharma and its wholly-owned subsidiaries Designer Diagnostics Inc. and ReceptoPharm (collectively “the Company”, “us”, “we” or “our”). We operate as one reportable segment. Designer Diagnostics Inc. has been inactive since June 2011. All intercompany transactions and balances have been eliminated in consolidation. Liquidity and Going Concern Our Unaudited Condensed Consolidated Financial Statements are presented on a going concern basis, which contemplate the realization of assets and satisfaction of liabilities in the normal course of business. We have experienced recurring, significant losses from operations, and have an accumulated deficit of $65,681,240 at March 31, 2020. In addition, we have a significant amount of indebtedness in default, a working capital deficit of $8,866,563 and a stockholders’ deficit of $8,928,291 at March 31, 2020. There is substantial doubt regarding our ability to continue as a going concern which is contingent upon our ability to secure additional financing, increase ownership equity and attain profitable operations. In addition, our ability to continue as a going concern must be considered in light of the problems, expenses and complications frequently encountered in established markets and the competitive environment in which we operate. We do not have sufficient cash to sustain our operations for a period of twelve months from the issuance date of this report and will require additional financing in order to execute our operating plan and continue as a going concern. Since our sales are not currently adequate to fund our operations, we continue to rely principally on debt and equity funding; however, proceeds from such funding have not been sufficient to execute our business plan. Our plan is to attempt to secure adequate funding until sales of our pain products are adequate to fund our operations. We cannot predict whether additional financing will be available, and/or whether any such funding will be in the form of equity, debt, or another form. In the event that these financing sources do not materialize, or if we are unsuccessful in increasing our revenues and profits, we will be unable to implement our current plans for expansion, repay our obligations as they become due and continue as a going concern. The accompanying Unaudited Condensed Consolidated Financial Statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern. Impact of COVID-19 on our Operations The ramifications of the outbreak of the novel strain of COVID-19, reported to have started in December 2019 and spread globally, are filled with uncertainty and changing quickly. Our operations have continued during the COVID-19 pandemic and we have not had significant disruption. Beginning in June 2020, the Company experienced a delay in retail rollout as a downstream implication of the slowing economy. We also closed our Coral Springs office in effort to save money. During May 2020, we received approval from SBA to fund our request for a PPP loan for $64,895. We used the proceeds primarily for payroll costs. We expect forgiveness of this loan under the current terms of requirement by the SBA. During April and June 2020, we obtained the loan in the amount of $150,000 from SBA under its Economic Injury Disaster Loan assistance program. We used the proceeds primarily for rent, payroll, utilities, accounting and legal expenses (See Note 12). The Company is operating in a rapidly changing environment so the extent to which COVID-19 impacts its business, operations and financial results from this point forward will depend on numerous evolving factors that the Company cannot accurately predict. Those factors include the following: the duration and scope of the pandemic; governmental, business and individuals’ actions that have been and continue to be taken in response to the pandemic; and the distribution of testing and a vaccine. Use of Estimates The accompanying Unaudited Condensed Consolidated Financial Statements are prepared in accordance with accounting principles generally accepted in the United States of America which require management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense. Significant estimates include our ability to continue as a going concern, the recoverability of inventories and long-lived assets, the recoverability of amounts due from officer, the valuation of stock-based compensation and certain debt and derivative liabilities, recognition of loss contingencies and deferred tax valuation allowances. Actual results could differ from those estimates. Changes in facts and circumstances may result in revised estimates, which would be recorded in the period in which they become known. Revenue from Contracts with Customers The Company accounts for revenue from contracts with customers in accordance with Financial Accounting Standard Board (“FASB”) Accounting Standard Codification (“ASC”) Topic 606, Revenue from Contracts with Customers Our revenues are primarily derived from customer orders for the purchase of our products. We recognize revenues as performance obligations are fulfilled upon shipment of products. We record revenues net of promotions and discounts. For certain product sales to a distributor, we record revenue including a portion of the cash proceeds that is remitted back to the distributor. Accounting for Shipping and Handling Costs We account for shipping and handling as fulfillment activities and record amounts billed to customers as revenue and the related shipping and handling costs as cost of sales. Accounts Receivable and Allowance for Doubtful Accounts We grant credit without collateral to our customers based on our evaluation of a particular customer’s credit worthiness. Accounts receivable are due 30 days after the issuance of the invoice. In addition, allowances for doubtful accounts are maintained for potential credit losses based on the age of the accounts receivable and the results of periodic credit evaluations of our customers’ financial condition. Accounts receivable are written off after collection efforts have been deemed to be unsuccessful. Accounts written off as uncollectible are deducted from the allowance for doubtful accounts, while subsequent recoveries are netted against the provision for doubtful accounts expense. We generally do not charge interest on accounts receivable. We use third party payment processors and are required to maintain reserve balances, which are included in accounts receivable. Accounts receivable are stated at estimated net realizable value. Accounts receivable are comprised of balances due from customers net of estimated allowances for uncollectible accounts. No allowance for doubtful account is deemed to be required at March 31, 2020 and December 31, 2019. Inventories Inventories, which are stated at the lower of average cost or net realizable value, consist of packaging materials, finished products, and raw venom that is utilized to make the API (active pharmaceutical ingredient). The raw unprocessed venom has an indefinite life for use. Commencing on October 1, 2019, we classify inventory as short-term or long-term inventory based on timing of when it is expected to be consumed. The Company regularly reviews inventory quantities on hand. If necessary, it records a net realizable value adjustment for excess and obsolete inventory based primarily on its estimates of product demand and production requirements. Write-downs are charged to cost of goods sold. We performed an evaluation of our inventory and related accounts at March 31, 2020 and December 31, 2019, and increased the reserve on supplier advances for future venom purchases included in prepaid expenses and other current assets by $0 and $23,948, respectively. At both March 31, 2020 and December 31, 2019, the total valuation allowance for prepaid venom was $224,859. Financial Instruments and Concentration of Credit Risk Our financial instruments include cash, accounts receivable, accounts payable, accrued expenses, loans payable, due to officers and derivative financial instruments. Other than certain warrant and convertible instruments (derivative financial instruments) and liabilities to related parties (for which it was impracticable to estimate fair value due to uncertainty as to when they will be satisfied and a lack of similar type transactions in the marketplace), we believe the carrying values of our financial instruments approximate their fair values because they are short term in nature or payable on demand. Our derivative financial instruments are carried at a measured fair value. Balances in various cash accounts may at times exceed federally insured limits. We have not experienced any losses in such accounts. We do not hold or issue financial instruments for trading purposes. In addition, for the three months ended March 31, 2020, there was one customer that accounted for 59% of the total revenues. For the three months ended March 31, 2019, there were two customers that accounted for 61% and 17% of the total revenues, respectively. As of March 31, 2020 and December 31, 2019, 100% of the accounts receivable balance are reserves due from two payment processors. Operating Lease Right-of-Use Asset and Liability In February 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-02, Leases The Company elected the package of practical expedients as permitted under the transition guidance, which allowed us: (1) to carry forward the historical lease classification; (2) not to reassess whether expired or existing contracts are or contain leases; and, (3) not to reassess the treatment of initial direct costs for existing leases. In accordance with ASC Topic 842, at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset, whether we obtain the right to substantially all the economic benefit from the use of the asset, and whether we have the right to direct the use of the asset. Leases with a term greater than one year are recognized on the balance sheet as ROU assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less under practical expedient in paragraph ASC 842-20-25-2. Lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected lease term. The implicit rate within our operating leases are generally not determinable and, therefore, the Company uses the incremental borrowing rate at the lease commencement date to determine the present value of lease payments. The determination of the Company’s incremental borrowing rate requires judgment. The Company determines the incremental borrowing rate for each lease using our estimated borrowing rate. Derivative Financial Instruments Management evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to income. For option-based simple derivative financial instruments, the Company uses the Black-Scholes option-pricing model to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date. We do not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. Convertible Debt For convertible debt that does not contain an embedded derivative that requires bifurcation, the conversion feature is evaluated to determine if the rate of conversion is below market value and should be categorized as a beneficial conversion feature (“BCF”). A BCF related to debt is recorded by the Company as a debt discount and with the offset recorded to equity. The related convertible debt is recorded net of the discount for the BCF. The discount is amortized as additional interest expense over the term of the debt with the resulting debt discount being accreted over the term of the note. The Fair Value Measurement Option We have elected the fair value measurement option for convertible debt with embedded derivatives that require bifurcation, and record the entire hybrid financing instrument at fair value under the guidance of ASC Topic 815, Derivatives and Hedging Derivative Accounting for Convertible Debt and Options and Warrants The Company evaluated the terms and conditions of the convertible debt under the guidance of ASC Topic 815, Derivatives and Hedging Embedded Derivatives Property and Equipment Property and equipment is recorded at cost. Expenditures for major improvements and additions are added to property and equipment, while replacements, maintenance and repairs which do not extend the useful lives are expensed. Depreciation is computed using the straight-line method over the estimated useful lives of the assets of 3 – 7 years. Long-Lived Assets The carrying value of long-lived assets is reviewed annually and on a regular basis for the existence of facts and circumstances that may suggest impairment. If indicators of impairment are present, we determine whether the sum of the estimated undiscounted future cash flows attributable to the long-lived asset in question is less than its carrying amount. If less, we measure the amount of the impairment based on the amount that the carrying value of the impaired asset exceeds the discounted cash flows expected to result from the use and eventual disposal of the impaired assets. Income Taxes The Company recorded no income tax expense for the three months ended March 31, 2020 and 2019 because the estimated annual effective tax rate was zero. As of March 31, 2020, the Company continues to provide a valuation allowance against its net deferred tax assets since the Company believes it is more likely than not that its deferred tax assets will not be realized. Stock-Based Compensation We account for stock-based compensation in accordance with FASB ASC Topic 718, Stock Compensation Net Income (Loss) Per Share Net income (loss) per share is calculated in accordance with FASB ASC Topic 260, Earnings per Share Three Months Ended March 31, 2020 2019 Basic and diluted numerator: Net income (loss) - basic $ 2,183,044 $ (400,443 ) Effect of dilutive securities: Change in fair value of convertible notes (2,854,140 ) - Interest on convertible debt 8,735 - Net loss - diluted $ (662,361 ) $ (400,443 ) Basic and diluted denominator: Weighted-average common shares outstanding - basic 6,272,328,529 4,112,446,110 Effect of dilutive securities: Convertible debt 6,020,875,493 - Weighted-average common shares outstanding - diluted (1) 12,293,204,022 4,112,446,110 Net income (loss) per share - basic and diluted $ (0.00 ) $ (0.00 ) (1) Includes potential common shares that are in excess of authorized shares. As of March 31, 2020 and 2019, the following items were not included in dilutive loss as the effect is anti-dilutive: March 31, 2020 March 31, 2019 Options and warrants 46,500,000 122,600,000 Convertible notes payable at fair value - 6,972,376,110 Convertible notes payable - 1,237,780,833 Total 46,500,000 8,332,756,943 Recent Accounting Pronouncements In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes In August 2020, the FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity All other newly issued accounting pronouncements but not yet effective have been deemed either immaterial or not applicable. |
Fair Value Measurements
Fair Value Measurements | 3 Months Ended |
Mar. 31, 2020 | |
Fair Value Disclosures [Abstract] | |
Fair Value Measurements | 2. FAIR VALUE MEASUREMENTS Certain assets and liabilities that are measured at fair value on a recurring basis at March 31, 2020 and December 31, 2019 are measured in accordance with FASB ASC Topic 820-10-05, Fair Value Measurements The statement requires fair value measurement be classified and disclosed in one of the following three categories: Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical unrestricted assets or liabilities; Level 2: Quoted prices in markets that are not active or inputs which are observable either directly or indirectly for substantially the full term of the asset or liability; and Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity). The following table summarizes our financial instruments measured at fair value at March 31, 2020 and December 31, 2019: Fair Value Measurements at March 31, 2020 Liabilities: Total Level 1 Level 2 Level 3 Warrant liability $ 866 $ - $ - $ 866 Derivative liabilities $ 1,145,655 $ - $ - $ 1,145,655 Convertible notes at fair value $ 2,562,049 $ - $ - $ 2,562,049 Fair Value Measurements at December 31, 2019 Liabilities: Total Level 1 Level 2 Level 3 Warrant liability $ 1,411 $ - $ - $ 1,411 Derivative liabilities $ 834,457 $ - $ - $ 834,457 Convertible notes at fair value $ 5,814,047 $ - $ - $ 5,814,047 The following table shows the changes in fair value measurements for the warrant liability using significant unobservable inputs (Level 3) during the three months ended March 31, 2020 and the year ended December 31, 2019: Description March 31, 2020 December 31, 2019 Beginning balance $ 1,411 $ 1,468 Total gain included in earnings (1) (545 ) (57 ) Ending balance $ 866 $ 1,411 (1) The gain related to the revaluation of our warrant liability is included in “Change in fair value of convertible notes and derivatives” in the accompanying consolidated statement of operations. We valued our warrants using a Dilution-Adjusted Black-Scholes Model. Assumptions used include (1) 0.17% to 1.59% risk-free rate, (2) warrant life is the remaining contractual life of the warrants, (3) expected volatility of 320%-348% (4) zero expected dividends (5) exercise price set forth in the agreements (6) common stock price of the underlying share on the valuation date, and (7) number of shares to be issued if the instrument is converted. We valued derivative liabilities using the number of potential convertible shares for warrants in equity and convertible notes with fixed conversion price that are recorded at amortized cost times the closing stock price of our restricted common stock at March 31, 2020. These derivative liabilities are recorded due to the fact that the number of shares of common stock issuable could exceed the Company’s authorized share limit and the equity environment is tainted, and therefore all convertible debt and options and warrants should be accounted for as liabilities. The following table summarizes assumptions and the significant terms of the convertible notes for which the entire hybrid instrument is recorded at fair value at March 31, 2020 and December 31, 2019: Conversion Price - Lower of Fixed Debenture Face Interest Default Discount Anti-Dilution % of stock price for look-back period Look-back March 31, 2020 $ 1,084,629 8%-10% 20%-24% N/A $0.00030-$0.00040 50%-60% 3 to 25 Days December 31, 2019 $ 1,244,204 8%-10% 20%-24% N/A $0.00010-$0.000293 50%-60% 3 to 25 Days Using the stated assumptions summarized in table above, we calculated the inception date and reporting period fair values of each note issued. The following table shows the changes in fair value measurements for the convertible notes at fair value using significant unobservable inputs (Level 3) during the three months ended March 31, 2020 and the year ended December 31, 2019: Description March 31, 2020 December 31, 2019 Beginning balance $ 5,814,047 $ 1,156,341 Purchases and issuances 15,425 688,274 Day one loss on value of hybrid instrument (1) 18,181 926,109 (Gain) loss from change in fair value (1) (2,871,776 ) 3,423,935 Debt discount 11,172 (22,344 ) Settlement through issuance of common stock - (83,268 Conversion to common stock (425,000 ) (275,000 ) Ending balance $ 2,562,049 $ 5,814,047 (1) The (gains) losses related to the valuation of the convertible notes are included in “Change in fair value of convertible notes and derivatives” in the accompanying consolidated statement of operations. |
Inventories
Inventories | 3 Months Ended |
Mar. 31, 2020 | |
Inventory Disclosure [Abstract] | |
Inventories | 3. INVENTORIES Inventories are valued at the lower of cost or net realizable value on an average cost basis. At March 31, 2020 and December 31, 2019, inventories were as follows: March 31, 2020 December 31, 2019 Raw Materials $ 65,568 $ 52,183 Finished Goods 6,624 8,177 Total Inventories 72,192 60,360 Less: Long-term inventory (65,568 ) (52,183 ) Current portion $ 6,624 $ 8,177 |
Property and Equipment
Property and Equipment | 3 Months Ended |
Mar. 31, 2020 | |
Property, Plant and Equipment [Abstract] | |
Property and Equipment | 4. PROPERTY AND EQUIPMENT Property and equipment consists of the following at March 31, 2020 and December 31, 2019: March 31, 2020 December 31, 2019 Computer equipment $ 25,120 $ 25,120 Furniture and fixtures 34,757 34,757 Lab equipment 53,711 53,711 Telephone equipment 12,421 12,421 Office equipment – other 16,856 16,856 Leasehold improvements 73,168 73,168 Total 216,033 216,033 Less: Accumulated depreciation (209,982 ) (209,270 ) Property and equipment, net $ 6,051 $ 6,763 We review our long-lived assets for recoverability if events or changes in circumstances indicate the assets may be impaired. At March 31, 2020, we believe the carrying values of our long-lived assets are recoverable. Depreciation expense for the three months ended March 31, 2020 and 2019 was $712 and $1,105, respectively. |
Due To_From Officer
Due To/From Officer | 3 Months Ended |
Mar. 31, 2020 | |
Related Party Transactions [Abstract] | |
Due to/from Officer | 5. DUE TO/FROM OFFICER At March 31, 2020, the balance due to our President and CEO, Rik Deitsch, is $199,290, which is an unsecured demand loan that bears interest at 4%. During the three months ended March 31, 2020, we advanced $4,200 to and collected $118,500 from Mr. Deitsch and the companies owned by him. Additionally, accrued interest on the demand loan was $1,678 and is included in the due to officer account. The Company has fully reserved receivables from companies owned by the Company’s CEO. The reserve was $524,970 and $564,470 as of March 31, 2020 and December 31, 2019, which represents a full valuation allowance for amounts owed by these companies. For the three months ended March 31, 2020 and 2019, we recorded a bad debt recovery of $39,500 and $0, respectively. At December 31, 2019, the balance due to our President and CEO, Rik Deitsch, is $122,812, which is an unsecured demand loan that bears interest at 4%. During the year ended December 31, 2019, we advanced $134,015 to and collected $5,000 from Mr. Deitsch and the companies owned by him. Additionally, accrued interest on the demand loan was $6,330 and is included in the due to officer account. |
Debts
Debts | 3 Months Ended |
Mar. 31, 2020 | |
Debt Disclosure [Abstract] | |
Debts | 6. DEBTS Debts consist of the following at March 31, 2020 and December 31, 2019: March 31, 2020 December 31, 2019 Note payable– Related Party (1) $ 14,400 $ 14,400 Notes payable – Unrelated third parties (Net of discount of $19,947 and $8,921, respectively) (2) 1,394,693 1,385,163 Convertible notes payable – Unrelated third parties (Net of discount of $15,893 and $17,370, respectively) (3) 899,407 872,256 Convertible notes payable, at fair value (Net of discount of $11,172 and $22,344, respectively) (4) 2,562,049 5,814,047 Other advances from an unrelated third party (5) 200,000 175,000 Ending balances 5,070,549 8,260,866 Less: Long-term portion-Convertible Notes payable-Unrelated third parties (225,597 ) (907,912 ) Current portion $ 4,844,952 $ 7,352,954 (1) During 2010 we borrowed $200,000 from one of our directors. Under the terms of the loan agreement, this loan was expected to be repaid in nine months to a year from the date of the loan along with interest calculated at 10% for the first month plus 12% after 30 days from funding. We are in default regarding this loan. The loan is under personal guarantee by Mr. Deitsch. We repaid principal balance in full as of December 31, 2016. At March 31, 2020 and December 31, 2019, we owed this director accrued interest of $164,276 and $159,555, respectively. The interest expense for the three months ended March 31, 2020 and 2019 was $4,721 and $4,196, respectively. In December 2017, we issued a promissory note to a related party in the amount of $12,000 with original issuance discount of $2,000. The note was amended in December 2018 with original issuance discount of $2,400 and was due in twelve months from the execution and funding of the note. At March 31, 2020 and December 31, 2019, the principal balance of the loan is $14,400. The Note was settled in June 2020. (2) At March 31, 2020 and December 31, 2019, the balance of $1,394,693 and $1,385,163 net of discount of $19,947 and $8,921, respectively, consisted of the following loans: ● In August 2016, we issued two Promissory Notes for a total of $200,000 ($100,000 each) to a company owned by a former director of the Company. The notes carry interest at 12% annually and were due on the date that was six-months from the execution and funding of the note. Upon default in February 2017, the Notes became convertible at $0.008 per share. During March 2017, we repaid principal balance of $6,365. During April 2017, the Notes with accrued interest were restated. The restated principal balance of $201,818 bears interest at 12% annually and was due October 12, 2017. During June 2017, we repaid principal balance of $8,844. The loan was reclassified to notes payable – unrelated third parties after the director resigned in March 2018. At December 31, 2018, we owed principal balance of $192,974, and accrued interest of $40,033. The principal balance of $101,818 and accrued interest of $21,023 were settled on February 15, 2019 for $104,000 with scheduled payments through May 1, 2020 (See Note 12) ● On August 2, 2011 under a settlement agreement with Liquid Packaging Resources, Inc. (“LPR”), we agreed to pay LPR a total of $350,000 in monthly installments of $50,000 beginning August 15, 2011 and ending on February 15, 2012. This settlement amount was recorded as general and administrative expenses on the date of the settlement. We did not make the December 2011 or January 2012 payments and on January 26, 2012, we signed the first amendment to the settlement agreement where we agreed to pay $175,000, which was the balance outstanding at December 31, 2011(this includes a $25,000 penalty for non-payment). We repaid $25,000 during the three months ended March 31, 2012. We did not make all of the payments under such amendment and as a result pursuant to the original settlement agreement, LPR had the right to sell 142,858 shares (5,714,326 shares pre reverse stock split) of our free trading stock held in escrow by their attorney and receive cash settlements for a total amount of $450,000 (the initial $350,000 plus total default penalties of $100,000). The $100,000 penalty was expensed during 2012. LPR sold the note to Southridge Partners, LLP (“Southridge”) for consideration of $281,772 in June 2012. In August 2013 the debt of $281,772 reverted back to LPR. ● At December 31, 2012, we owed University Centre West Ltd. approximately $55,410 for rent, which was assigned and sold to Southridge, and it is currently outstanding and carries no interest. ● In April 2016, we issued a promissory note to an unrelated third party in the amount of $10,000 bearing interest at 10% annually. The note was due in one year from the execution and funding of the note. The note is in default and negotiation of settlement. At March 31, 2020 and December 31, 2019, the accrued interest is $4,006 and $3,755, respectively. ● In May 2016, the Company issued a promissory note to an unrelated third party in the amount of $75,000 bearing monthly interest at a rate of 2%. The note was due in six months from the execution and funding of the note. During April 2017, we accepted the offer of a settlement to issue 5,000,000 common shares as a repayment of $25,000. The note is in default and in negotiation of settlement. At March 31, 2020 and December 31, 2019, the outstanding principal balance is $50,000 and accrued interest is $53,001 and $49,967, respectively. ● In June 2016, the Company issued a promissory note to an unrelated third party in the amount of $50,000 bearing monthly interest at a rate of 2%. The note was due in six months from the execution and funding of the note. The note is in default and negotiation of settlement. At March 31, 2020 and December 31, 2019, the outstanding principal balance is $50,000 and accrued interest is $46,200 and $43,166, respectively. ● In August 2016, we issued a promissory note to an unrelated third party in the amount of $150,000 bearing monthly interest at a rate of 2.5%. The note was due in six months from the execution and funding of the note. During April 2017, the note with accrued interest was restated. The restated principal balance of $180,250 bears monthly interest at a rate of 2.5% and was due October 20, 2017. During January 2018, the note with accrued interest was restated. The restated principal balance of $220,506 bears monthly interest at a rate of 2.5% and was due July 12, 2018. In connection with this restated note, we issued 2,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $2,765 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Amortization for the debt discount for the year ended December 31, 2018 was $2,765. During July 2018, we issued 5,000,000 restricted shares due to the default on repayment of the promissory note of $220,506 restated in January 2018. The shares were valued at fair value of $5,500. During December 2018, the note with accrued interest was restated. The restated principal balance of $282,983 bears monthly interest at a rate of 2.0% and was due June 17, 2019. In connection with this restated note, we issued 10,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $3,945 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Amortization for this debt discount for the years ended December 31, 2019 and 2018 was $3,616 and $329, respectively. During September 2019, the notes of $282,983 plus accrued interest amended in December 2018 were restated. The restated principal balance of $333,543 were due September 2020. In connection with this restated note, we issued 20,000,000 shares of our common stock. The common stock was valued at $5,895 and recorded as a debt discount that was amortized over the life of the note. Amortization for this debt discount for the year ended December 31, 2019 was $1,474 and debt discount at December 31, 2019 is $4,421. Amortization for this debt discount for the three months ended March 31, 2020 was $1,474 and debt discount at March 31, 2020 is $2,947. The Note is in default and negotiation of settlement. At March 31, 2020 and December 31, 2019, the principal balance is $333,543, and the accrued interest is $45,362 and $25,127, respectively. ● On September 26, 2016, we issued a promissory note to an unrelated third party in the amount of $75,000 bearing interest at 10% annually. The note was due in one year from the execution and funding of the note. In March 2018, $15,000 of the principal balance of the note was assigned to an unrelated third party and is in negotiation of settlement. In January 2019, the remaining principal balance of $60,000 and accrued interest of $15,900 was restated in the form of a Convertible Note (See Note 6(4)). At March 31, 2020 and December 31, 2019, the principal balance outstanding is $15,000, and the accrued interest is $1,371. ● In October 2016, we issued a promissory note to an unrelated third party in the amount of $50,000 bearing monthly interest at a rate of 2%. The note was due in six months from the execution and funding of the note. The note is in default and in negotiation of settlement. At March 31, 2020 and December 31, 2019, the accrued interest is $42,500 and $39,466, respectively. ● In June 2017, we issued a promissory note to an unrelated third party in the amount of $12,500 bearing interest at 10% annually. The note was due in one year from the execution and funding of the note. The note is in default and in negotiation of settlement. At March 31, 2020 and December 31, 2019, the accrued interest is $3,528 and $3,212, respectively. ● During July 2017, we received a loan for a total of $200,000 from an unrelated third party. The loan was repaid through scheduled payments through August 2017 along with interest on average 15% annum. We have recorded loan costs in the amount of $5,500 for the loan origination fees paid at inception date. The debt discount was fully amortized as of December 31, 2018. During June 2018, the loan was settled with two unrelated third parties for $130,401 and $40,000, respectively, with the monthly scheduled repayments of approximately $5,000 and $2,000 per month to each unrelated party through July 2020. We recorded a gain on settlement of debt in other income for $20,927 in June 2018. The Company repaid a total of $34,976 and $42,698 during 2018 and 2019, respectively. The Company repaid $12,694 during the three months ended March 31, 2020. At March 31, 2020 and December 31, 2019, the principal balance is $80,034 and $92,728, respectively. The portion of settlement of $130,401 was repaid in full in April 2021. The remaining balance of $33,874 is in default and negotiation of settlement. ● In July 2017, we issued a promissory note to an unrelated third party in the amount of $50,000 with original issue discount of $10,000. The note was due in six months from the execution and funding of the note. The original issuance discount was fully amortized as of March 31, 2018. The note is in default and in negotiation of settlement. At March 31, 2020 and December 31, 2019, the principal balance of the note is $50,000. ● In September 2017, we issued a promissory note to an unrelated third party in the amount of $36,000 with original issue discount of $6,000. During September 2018 and 2019, the Note was amended with original issuance discount of $6,000 due in September 2019 and 2020. The Note was further restated in September 2020. The restated principal balance was $33,000 with the original issuance discount of $3,000 and was due March 2021. The original issue discount is amortized over the term of the loan. Amortization for the debt discount for the years ended 2019 and 2018 was $7,500 and $4,000, respectively. Repayments of $1,500, $7,000 and $5,000 have been made during 2017, 2018 and 2019, respectively. Additionally, repayment of $2,000 was made during the three months ended March 31, 2020. The Note is under personal guarantee by Mr. Deitsch. At March 31, 2020 and December 31, 2019, the principal balance of the note is $29,500 and $30,000, net of debt discount of $3,000 and $4,500, respectively. During March 2021, the remaining balance of $30,000 was sold to an unrelated third party in the form of a convertible note at a fixed conversion price of $0.01 per share. The new note carries interest at 12% with scheduled monthly payments of $1,000 beginning in April 2021 through March 2024. ● In October 2017, we issued a promissory note to an unrelated third party in the amount of $50,000 with original issuance discount of $10,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $3,200 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. At December 31, 2017, the principal balance of the note is $60,000. Debt discount and original issuance discount were fully amortized as of December 31, 2018. During April 2018, we issued a total of 1,000,000 restricted shares to a Note holder due to the default on repayment. The shares were valued at fair value of $1,700. During April 2018, the Note was restated in the amount of $60,000 including the original issuance discount of $10,000 due October 2018. In connection with this restated note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $8,678 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discount and original issuance discount for a total of $18,678 have been fully amortized as of December 31, 2018. During November 2018, the Note was restated in the amount of $60,000 including the original issuance discount of $10,000 due May 2019. In connection with this restated note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $2,381 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Pursuant to the restatement of the Note, the Company agreed that the original issuance discount of $10,000 from the April 2018 Note would be paid to the lender upon execution of restated Note in November 2018. The settlement agreement executed in December 2018 provides that 10,000,000 shares are issued due to the late payment. The shares were valued at $3,000. During July 2019, payment of original issuance discount of $10,000 was made. During September 2019, we issued additional 10,000,000 restricted shares due to the late payment of the original issuance discount of $10,000. The shares were valued at fair value of $4,000. The restated Note in November 2018 and prior notes are all under personal guarantee by Mr. Deitsch. Amortization of debt discount and original issuance discount for the three months ended March 31, 2020 and 2019 was $0 and $4,127, respectively, for the restated Note in November 2018. The total debt discounts of $12,381 were fully amortized as of June 30, 2019. As of December 31, 2019, the amount due is $60,000. During January 2020, the Note of $60,000 and the Note of $76,076 (See Note 6(3)) plus accrued interest of $12,149 were combined and restated at a rate of 2.0% monthly due July 2020. At March 31, 2020, the restated principal balance and accrued interest was $148,225 and $7,710, respectively. The principal balance plus accrued interest was further restated in July 2020 and February 2021 and is due in August 2021(See Note 12). ● In November 2017, we issued a promissory note to an unrelated third party in the amount of $120,000 with original issuance discount of $20,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 10,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $5,600 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discounts were fully amortized as of December 31, 2018. 1,500,000 shares of common stocks were issued due to the default of repayments with a fair value of $2,250 in May 2018. During March 2020, $50,000 of the Note of $120,000 with original issuance discount of $20,000 originated in November 2017 was settled for 125,000,000 shares with a fair value of $87,500. We recorded a loss on settlement in other expense for $37,500 (See Note 7). An additional 46,000,000 shares with a fair value of $32,200 were issued due to the default on repayment of the promissory note. The remaining balance of $70,000 was restated with additional issuance discount of $14,000. The $84,000 due in September 2020 is in default and negotiation of further settlement. At March 31, 2020 and December 31, 2019, the principal balance of the loan is $70,000 and $120,000, net of discount of $14,000 and $0, respectively. ● In November 2017, we issued a promissory note to an unrelated third party in the amount of $18,000 with original issuance discount of $3,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $2,900 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discounts were fully amortized as of December 31, 2018. The note is in default and in negotiation of settlement. In September 2018, 7,000,000 shares of common stock were issued due to the default of repayments with a fair value of $5,600. At March 31, 2020 and December 31, 2019, the principal balance of the note is $18,000 and the accrued interest is $2,000. (3) At March 31, 2020 and December 31, 2019, the balance of $899,407 and $872,256 net of discount of $15,893 and $17,370, respectively, consisted of the following convertible loans: ● During July 2016, we issued a convertible note to an unrelated third party in the amount of $50,000 bearing monthly interest at a rate of 2.0% and convertible at $0.05 per share. During January 2017, the Note was restated with principal amount of $56,567 bearing monthly interest rate of 2.5%. The New Note of $56,567 was due on July 26, 2017 and convertible at $0.05 per share. During February 2018, the Notes with accrued interest of $65,600 was restated. The restated principal balance of $65,600 bears monthly interest at a rate of 2.5% and was due August 14, 2018. In connection with this restated note, we issued 1,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $4,035 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discount was fully amortized as of December 31, 2018. During August 2018, the Notes with accrued interest of $10,476 were restated. The restated principal balance of $76,076 bears monthly interest at a rate of 2.5% and was due February 2019. In connection with this restated note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $3,800 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Amortization of debt discount of $2,850 has been recorded as of December 31, 2018. The remaining debt discount of $950 was fully amortized during the three months ended March 31, 2019. The note is under personal guarantee by Mr. Deitsch. At December 31, 2019, the convertible note payable was recorded at $76,076 with accrued interest of $12,149. During January 2020, this Note and the Note of $60,000 amended in November 2018(See Note 6(2)) were combined and restated with principal balance of $148,225(See Note 12). ● In October 2017, we issued a promissory note to an unrelated third party in the amount of $60,000 with original issuance discount of $10,000 and a conversion option. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $3,300 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discounts were fully amortized as of December 31, 2018. The loan is in default and in negotiation of settlement. In April 2018, 1,000,000 shares of common stock were issued due to the default of repayments with a fair value of $1,500. At March 31, 2020 and December 31, 2019, the principal balance of the note is $60,000. ● During January through December 2018, we issued convertible notes payable to the 20 unrelated third parties for a total of $618,250 with original issue discount of $62,950. The notes are due in six months from the execution and funding of each note. The notes are convertible into shares of Company’s common stock at a conversion price ranging from $0.0003 to $0.001 per share. The difference between the conversion price and the fair value of the Company’s common stock on the date of issuance of the convertible notes resulted in a beneficial conversion feature in the amount of $249,113. In addition, upon the issuance of convertible notes, the Company issued 10,250,000 shares of common stock. The Company has recorded a debt discount in the amount of $6,542 to reflect the value of the common stock as a reduction to the carrying amount of the convertible debt and a corresponding increase to common stock and additional paid-in capital. The total discount of $255,655 and original issuance discount of $62,950 was amortized over the term of the debt. At December 31, 2018, the principal balance of the notes, net of discount of $28,421 was $589,829. During February 2019, we issued convertible notes payable of $70,000 with original issuance discount of $5,000. The notes were due in six months from the execution and funding of each note. The notes are convertible into shares of Company’s common stock at a conversion price of $0.0005 per share. During December 2019, $22,000 of the Note was amended to extend the maturity date to June 2020. In connection with the issuance and restatements of the notes, the Company granted the following warrants at an exercise price of $0.001 per share in 2019. The warrants were valued using the Black-Scholes method and recorded as a debt discount that was amortized over the life of the notes. The Notes were further restated in August and October 2020 and are currently in default and in negotiation of settlement. Month of Issuance Number of Warrants Fair Value of Warrants Month of Expiration February, 2019 110,000,000 $ 8,147 August, 2019 December, 2019 44,000,000 $ 7,370 August, 2020 During May 2019, we restated two convertible notes payable with additional original issue discount of $6,400 and issued 6,000,001 shares of common stock with a fair value of $1,800. The two restated notes were due in August 2019 and are in default. The total discount of $8,200 was amortized over the term of the notes. During November and December 2019, we issued two convertible promissory notes to two unrelated third parties for $159,500 with original issuance discount of $14,500. The notes were due six months from the execution and funding of each note. The Noteholder had the right to convert the note into shares of Common Stock at a fixed conversion price ranging from $0.0002 to$0.000275. The Notes are in default and negotiation of settlement. During 2019, repayments of $13,500 were made in cash to three of the Notes. Six of the Notes for a total of $87,100 were repaid in stocks as the part of settlement of issuances of 800,000,000 shares of common stocks during December 2019. Amortization for the year ended December 31, 2019 was $55,222. Additionally, $9,185 was amortized during the three months ended March 31, 2020. At December 31, 2019, the principal balance of the notes, net of discount of $17,370 is $736,180. Two of the above mentioned convertible notes payable for a total of $19,500 was settled in full in March and April 2021(See Note 12). During the three months ended March 31, 2020, we issued convertible notes payable of $101,750 with original issuance discount of $9,250. Amortization for this discount for the three months ended March 31, 2020 was $1,542. $33,000 of the notes were due in six months from the execution and funding of each note. $68,750 of the notes were due in one year from the execution and funding of each note. The notes are convertible into shares of Company’s common stock at a conversion price ranging from $0.002 to 0.0005 per share. At March 31, 2020, the principal balance of the notes, net of discount of $15,893 is $839,407. At the date of this report, all of the above mentioned convertible notes payable of $915,300 are in default and in negotiation of settlement. (4) At March 31, 2020 and December 31, 2019, the balance of $2,562,049 and $5,814,047 net of discount of $11,172 and $22,344, respectively, consisted of the following convertible loans: ● On March 28, 2016, we signed an expansion agreement with Brewer and Associates Consulting, LLC (“B+A”) to the original consulting agreement dated on October 15, 2015 for consulting services for twelve months for a monthly fee of $7,000. To relieve our cash obligation of $36,000 per original agreement, we issued three convertible notes for a total of $120,000 which includes the fees due under the original agreement and the new monthly fees due under the expansion agreement. The $40,000 and $60,000 of the Notes were paid in full as of December 31, 2016 and December 31, 2017, respectively. The remaining balance of $20,000 Notes is in default and negotiation of settlement. The conversion price is equal to 55% of the average of the three lowest volume weighted average prices for the three consecutive trading days immediately prior to but not including the conversion date. At March 31, 2020 and December 31, 2019, the convertible notes payable with principal balance of $20,000, at fair value, were recorded at $50,687 and $56,373, respectively. ● During May 2017, we issued a Convertible Debenture in the amount of $64,000 to an unrelated third party. The note carries interest at 8% and was due on May 4, 2018, unless previously converted into shares of restricted common stock. We have accrued interest at default interest rate of 20% after the note’s maturity date. The Note holder has the right to convert the note into shares of Common Stock at a sixty percent (60%) of the lowest trading price of our restricted common stock for the twenty trading days preceding the conversion date. During November 2017, the Note holder made a conversion of our restricted common stocks satisfying the principal balance of $856 and penalty of $6,400 for a fair value of $21,399. During February 2018, the remaining balance of $63,144 with accrued interest and penalty of $12,442 was assigned and sold to three unrelated third parties. During June 2018, a Note holder made a conversion of 50,670,000 shares of our restricted common stock with a fair value of $70,938 in satisfaction of the balance of $34,060 plus accrued interest of $8,607. During December 2019, the principal balance of $16,752 with accrued interest of $3,232 assigned and sold to a third party was settled as the part of settlement of issuances of 800,000,000 shares of common stocks during December 2019. At March 31, 2020 and December 31, 2019, the remaining principal of $12,629 plus accrued interest of $10,143 and $9,782, at fair value, was recorded at $38,404 and $62,253. The remaining principal balance of the Note is in default. All of the convertible notes discussed below are with a single unrelated third party. ● During December 2016, we issued a Convertible Debenture to an unrelated third party in the amount of $110,000. The note carries interest at 12% and matured on September 8, 2017. Unless previously converted into shares of restricted common stock, the Note holder has the right to convert the note into shares of Common Stock at a sixty percent (60%) of the lowest trading prices of our restricted common stock for the twenty-five trading days preceding the conversion date. During June and July 2017, the Note holder made conversions of a total of 179,800,000 shares of stock satisfying the principal balance of $63,001 and accrued interest for a fair value of $298,575. During February 2018, the remaining balance of $46,999 with accrued interest of $2,820 was assigned and sold to an unrelated third party in the form of a Convertible Redeemable Note. As part of the debt sale, the Company entered into a settlement agreement with the original noteholder for a settlement of a default penalty of the original debt. During February and July, 2018, we issued a total of 105,157,409 shares of our restricted common stock to the original Note holder with a fair value of $147,220. At December 31, 2018, the Company owed additional shares to the original noteholder and recorded an accrual of $32,400 to account for the cost of the shares, and the shares were issued in January 2019. The new note of $49,819 carries interest at 8% and was due on February 13, 2019, unless previously converted into shares of restricted common stock. We have increased the outstanding principal due by 10% and accrued interest at default interest rate of 24% after the note’s maturity date. The Noteholder has the right to convert the note into shares of our restricted common stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five prior trading days including the conversion date. The conversion discount was further decreased to fifty percent due to the default on the Note. During September 2018, the Noteholder made a conversion of 52,244,433 shares of our restricted common stock with a fair value of $37,011 in satisfaction of principal balance of $15,000 and accrued interest in full. At March 31, 2020 and December 31, 2019, the convertible note payable with principal balance of $38,301, at fair value, was recorded at $103,311 and $246,819. ● During February 2018, we issued a convertible debenture in the amount of $200,000 to an unrelated third party. The note carries interest at 8% and was due in February 2019, unless previously converted into shares of restricted common stock. We have increased the outstanding principal due by 10% and accrued interest at default interest rate of 24% after the note’s maturity date. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. The conversion discount was further decreased to fifty percent due to the default on the Note. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $1,646,242. At March 31, 2020 and December 31, 2019, the convertible note payable with principal balance of $220,000, at fair value, was recorded at $591,197 and $1,412,175. The note carries additional $200,000 “Back-end Note” ($100,000 each) with the same terms as the original note. ● During April 2018, $65,000 of one of the $100,000 Back-end Note was funded. The note carries interest at 8% and was due in February 2019, unless previously converted into shares of restricted common stock. We have increased the outstanding principal due by 10% and accrued interest at default interest rate of 24% after the note’s maturity date. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. The conversion discount was further decreased to fifty per |
Stockholders' Deficit
Stockholders' Deficit | 3 Months Ended |
Mar. 31, 2020 | |
Equity [Abstract] | |
Stockholders' Deficit | 7 . STOCKHOLDERS’ DEFICIT Authorized Shares On March 7, 2018, we obtained written consents from stockholders holding a majority of our outstanding voting stock to approve an amendment of the Company’s articles of incorporation, as amended, to increase the number of authorized shares of common stock from 2,000,000,000 to 8,000,000,000. Series A Preferred Stock Effective October 30, 2017, pursuant to authority of its Board of Directors, the Company filed a Certificate of Determination to authorize the issuance of 20,000,000 shares of stock designated “preferred shares”, issuable from time to time in one or more series and authorize the Board of Directors to fix the number of shares constituting any such series, and to determine or alter the dividend rights, dividend rate, conversion rights, voting rights, right and terms of redemption (including sinking fund provisions), the redemption price or prices and the liquidation preference of any wholly unissued series of such preferred shares, and the number of shares constituting any such series. Effective October 30, 2017 the Board of Directors authorized the issuance of 3,000,000 shares of Series A Preferred Stock (“Series A Preferred”). Terms of the Series A Preferred include the following: 1. The Series A Preferred votes with the Company’s common stock as a single class on all matters or consents for the Company’s common stockholders. Each share of Series A Preferred is entitled to one thousand votes per share. 2. The Series A Preferred will not be entitled to dividends unless the Company pays cash dividends or dividends in other property to holders of outstanding shares of common stock, in which event, each outstanding share of the Series A Preferred will be entitled to receive dividends of cash or property in an amount or value equal to one thousand multiplied by the amount paid in respect of one share of common stock. Any dividend payable to the Series A Preferred will have the same record and payment date and terms as the dividend payable on the common stock. 3. Upon any voluntary or involuntary liquidation, dissolution or winding up of the Company, the holders of all shares of Series A Preferred then outstanding shall be entitled to be paid out of the assets of the Company available for distribution to its stockholders an amount in cash equal to $0.133 in cash per share before any distribution is made on any shares of the Company’s common stock. If upon any voluntary or involuntary liquidation, dissolution or winding up of the Company, the application of all amounts available for payments with respect to Series A Preferred would not result in payment in full of Series A Preferred, the holders shall share equally and ratably in any distribution of assets of the Company in proportion to the full liquidation preference to which each is entitled. 4. The Series A Preferred does not have any redemption rights. Common Stock Issued for Conversion of Convertible Debt During January and February 2020, the Note holder made conversions of a total of 500,000,000 shares of stock satisfying the principal balance of $175,000 of a Note originated in February 2019 in the amount of up to $1,000,000(See Note 6). Number of Fair Value of Date shares converted Debt Converted 1/21/2020 250,000,000 $ 150,000 2/18/2020 250,000,000 $ 275,000 Common Stock Issued for Settlement of Debt During March 2020, $50,000 of the Note of $120,000 with original issuance discount of $20,000 originated in November 2017 was settled for 125,000,000 shares with a fair value of $87,500. We recorded a loss on settlement in other expense for $37,500 (See Note 6). Common Stock Issued for Debt Modification and Penalty During January and March 2020, we issued a total of 121,000,000 shares to two Note holders due to the default on repayment of the promissory notes. The shares were valued at fair value of $77,200. Common Stock Issued for Services During June 2018, the Company signed an agreement with a consultant for investor relation services for twelve months. In connection with the agreement, 100,000,000 shares of the Company’s restricted common stocks were issued. The shares were valued at $0.0012 per share. The compensation charge of $120,000 has been fully amortized as of June 2019. The Company recorded an equity compensation charge of $0 and $30,000, respectively, during the three months ended March 31, 2020 and 2019. During April 2019, we signed an agreement with a consultant to provide investor relation services for twelve months. In connection with the agreement, 120,000,000 shares of our restricted common stock were issued. The shares were valued at $24,000. During June 2019, we signed an agreement with a consultant to provide investor relation services for twelve months. In connection with the agreement, 15,000,000 shares of our restricted common stock were issued. The shares were valued at $6,000. The equity compensation charge of $21,500 has been recorded during June through December 2019. $7,500 has been recorded during the three months ended March 31, 2020. The remaining unrecognized compensation cost of $1,000 will be recognized by the Company over the remaining service period. |
Stock Warrants
Stock Warrants | 3 Months Ended |
Mar. 31, 2020 | |
Share-based Payment Arrangement [Abstract] | |
Stock Warrants | 8. STOCK WARRANTS Common Stock Warrants On March 31, 2017, in connection with the issuance of an $80,000 Note, we granted three-year warrants to purchase an aggregate of 6,000,000 shares of our common stock at an exercise price of $0.005 per share. The warrants were valued at their fair value of $0 and $539 using the Black-Scholes method on March 31, 2020 and December 31, 2019. The warrants expired on March 30, 2020. On March 3, 2016, in connection with the issuance of a convertible note, we granted five-year warrants to purchase an aggregate of 2,500,000 shares of our common stock at an exercise price of $0.03 per share. The warrants were valued at their fair value of $866 and $872 using the Black-Scholes method at March 31, 2020 and December 31, 2019. The warrants expired on March 3, 2021. On April 4, 2016, in connection with the issuance of convertible notes, we granted three-year warrants to purchase an aggregate of 4,000,000 shares of our common stock at an exercise price of $0.05 per share. The warrants were valued at their fair value of $0 using the Black-Scholes method at December 31, 2018. The warrants expired on April 4, 2019. During April 2014, the Company issued a total of 100,000 warrants to purchase common stock at an exercise price of $0.025 per share in connection with issuance of a convertible note payable to Coventry. The warrants were valued at their fair value of $0 using the Black-Scholes method at December 31, 2018. The warrants expired on April 9, 2019. The Company granted the following warrants at an exercise price of $0.001 per share in connection with issuances of three convertible notes payable of $70,000 in February 2019 and amendment of one convertible notes payable of $22,000 in December 2019. The warrants were valued using the Black-Scholes method and recorded as a debt discount and additional paid in capital. No warrants have been exercised. Month of Issuance Number of Warrants Fair Value of Warrants Month of Expiration February, 2019 110,000,000 $ 8,147 August, 2019 December, 2019 44,000,000 $ 7,370 August, 2020 A summary of warrants outstanding in conjunction with private placements of common stock were as follows during the three months ended March 31, 2020 and the year ended December 31, 2019: Number Of shares Weighted average exercise price Balance December 31, 2018 12,600,000 $ 0.026 Exercised - - Issued 154,000,000 0.001 Expired (114,100,000 ) 0.0027 Balance December 31, 2019 52,500,000 $ 0.0028 Exercised - - Issued - - Expired (6,000,000 ) 0.005 Balance March 31, 2020 46,500,000 $ 0.0026 The following table summarizes information about fixed-price warrants outstanding as of March 31, 2020 and December 31, 2019 : Exercise Price Weighted Average Number Outstanding Weighted Average Contractual Life Weighted Average Exercise Price March 31, 2020 $ 0.001-0.03 46,500,000 0.42 years $ 0.0026 December 31, 2019 $ 0.001-0.03 10,187,671 0.62 years $ 0.0028 At March 31, 2020, the aggregate intrinsic value of all warrants outstanding and expected to vest was $0. The intrinsic value of warrant share is the difference between the fair value of our restricted common stock and the exercise price of such warrant share to the extent it is “in-the-money”. Aggregate intrinsic value represents the value that would have been received by the holders of in-the-money warrants had they exercised their warrants on the last trading day of the year and sold the underlying shares at the closing stock price on such day. The intrinsic value calculation is based on the $0.0006, the closing stock price of our restricted common stock on March 31, 2020. There were no in-the-money warrants at March 31, 2020. |
Accrued Expenses
Accrued Expenses | 3 Months Ended |
Mar. 31, 2020 | |
Payables and Accruals [Abstract] | |
Accrued Expenses | 9. ACCRUED EXPENSES Accrued expenses consisted of the following: March 31, 2020 December 31, 2019 Accrued consulting fees $ 161,550 $ 161,550 Accrued settlement expenses 35,000 35,000 Accrued payroll taxes 179,911 167,906 Accrued interest 238,354 231,186 Accrued others 15,459 16,905 Total $ 630,274 $ 612,547 |
Prepaid Expenses
Prepaid Expenses | 3 Months Ended |
Mar. 31, 2020 | |
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] | |
Prepaid Expenses | 10. PREPAID EXPENSES Prepaid expenses and other current assets consist of the following: March 31, 2020 December 31, 2019 Supplier advances for future purchases $ 224,859 $ 224,859 Reserve for supplier advances (224,859 ) (224,859 ) Net supplier advances - - Prepaid professional fees 20,265 8,650 Deferred stock compensation 1,000 8,500 Total $ 21,265 $ 17,150 We performed an evaluation of our inventory and related accounts at March 31, 2020 and December 31, 2019, and increased the reserve on supplier advances for future venom purchases by $0 and $23,948, respectively. At March 31, 2020 and December 31, 2019, the total valuation allowance for prepaid venom is $224,859. |
Commitments and Contingencies
Commitments and Contingencies | 3 Months Ended |
Mar. 31, 2020 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | 11. COMMITMENTS AND CONTINGENCIES Operating Leases In February 2016, we entered into our current three-year operating lease for monthly payments of approximately $3,200 which expired in February 2019. The lease is currently month-to-month, thus classified as short-term and not reported on the balance sheet under ASC 842. ReceptoPharm leases a lab and renewed its operating lease agreement for five years beginning August 1, 2017 for monthly payments of approximately $6,900 with a 5% increase each year. March 31, 2020 Lease cost Operating lease cost $ 22,255 Short-term lease cost 11,219 Total lease cost $ 33,474 Balance sheet information Operating ROU Assets $ 200,276 Operating lease obligations, current portion 75,588 Operating lease obligations, non-current portion 123,576 Total operating lease obligations $ 199,164 Weighted average remaining lease term (in years) – operating leases 2.42 Weighted average discount rate-operating leases 8 % Supplemental cash flow information related to leases were as follows, for the three months ended March 31, 2020: Cash paid for amounts included in the measurement of operating lease liabilities $ 32,437 Future minimum payments under these lease agreements are as follows: December 31, Total 2020(Remaining nine months) $ 66,339 2021 91,379 2022 62,274 Total future lease payments $ 219,992 Less imputed interest 20,828 Total $ 199,164 Consulting Agreements During July 2015, we signed an agreement with a company to provide for consulting services for five years. In connection with the agreement, 500,000 shares of our restricted common stock and a one year 8% note of $50,000 were granted. The shares were valued at $0.18 per share. As the services provided were in dispute, the shares and note payable have not been issued as of March 31, 2020 and December 31, 2019. We have accrued the $142,500 in accrued expense and equity compensation. During October 2015, the Company signed an agreement with a consultant for consulting services for a year. In connection with the agreement, 2,500,000 shares of the Company’s restricted common stock were granted and the Company was to make monthly cash payments of $3,000. As of December 31, 2016, the Company recorded an equity compensation charge of $31,750, however, only 1,000,000 of the shares have been issued. As of March 31, 2020 and December 31, 2019, $19,150 has been recorded in accrued expense to account for the 1,500,000 shares of common stock that have not been issued. Litigation Paul Reid et al. v. Nutra Pharma Corp. et al. On August 26, 2016, certain of former ReceptoPharm employees and a former ReceptoPharm consultant filed a lawsuit in the 17th Judicial Circuit in and for Broward County, Florida (Case No. CACE16–015834) against Nutra Pharma and Receptopharm to recover $315,000 allegedly owing to them under a settlement agreement reached in an involuntary bankruptcy action that was brought by the same individuals in 2012 and for payment of unpaid wages/breach of written debt confirms. On June 24, 2021, the parties entered into a confidential settlement agreement of the lawsuit. Nutra Pharma has fully performed under the settlement and considers the case fully resolved. Get Credit Healthy, Inc. v. Nutra Pharma Corp. and Rik Deitsch, Case No. CACE 18-017055 On August 1, 2018, Get Credit Healthy, Inc. filed a lawsuit against the Company and Rik Deitsch (collectively the “Defendants”) in the 17th Judicial Circuit Court in and for Broward County, Florida (Case No. CACE 18-017055) to recover $100,000 allegedly owed under an amended promissory note dated April 12, 2017. Counsel for Get Credit Healthy, Inc. requested an early mediation conference in an attempt to resolve our dispute. We agreed to this request, and mediation took place on February 15, 2019. At December 31, 2018, we owed principal balance of $101,818 and accrued interest of $21,023. The lawsuit was settled on February 15, 2019 for $104,000 and was further amended. The repayments were made in full as of November 2020 (See Note 6). CSA 8411, LLC v. Nutra Pharma Corp., Case No. CACE 18-023150 On October 12, 2018, CSA 8411, LLC filed a lawsuit against the Company in the 17th Judicial Circuit Court in and for Broward County, Florida (Case No. CACE 18-023150) to recover $100,000 allegedly owed under an amended promissory note dated April 12, 2017. On November 1, 2018, the Company filed its Answer and Affirmative Defenses to the Complaint. The Company believes that this lawsuit is without merit. Moreover, the Company believes that it has a number of valid defenses to this claim. Among other things, the owner of CSA 8411, LLC violated the terms of a Binding Memorandum of Understanding by failing to invest in the Company and fraudulently inducing the Company to enter into the subject amended promissory note (contrary to the Get Credit Healthy lawsuit discussed above, we are certain that this individual is the majority owner of CSA 8411, LLC). Opposing counsel reached out to schedule mediation, and mediation was set for June 21, 2019 in Plantation, FL however the mediation was unsuccessful. At March 31, 2020, we owed principal balance of $91,156 and accrued interest of $32,676 (See Note 6) if the defenses and our new claims are deemed to be of no merit. Defendant also filed affirmative claims against the Plaintiff, its owner Dan Oran and several related entities. The case has not been set for trial as of this date. Securities and Exchange Commission v. Nutra Pharma Corporation, Erik Deitsch, and Sean Peter McManus On September 28, 2018, the United States Securities and Exchange Commission (the “SEC”) filed a lawsuit in the United States District Court for the Eastern District of New York (Case No. 2:18-cv-05459) against the Company, Mr. Deitsch, and Mr. McManus. The lawsuit alleges that, from July 2013 through June 2018, the Company and the other defendants’ defrauded investors by making materially false and misleading statements about the Company and violated anti-fraud and other securities laws. The violations alleged against the Company by the SEC include: (a) raising over $920,000 in at least two private placement offerings for which the Company failed to file required registration statements with the SEC; (b) issuing a series of materially false or misleading press releases; (c) making false statements in at least one Form 10-Q; and (d) failing to make required public filings with the SEC to disclose the Company’s issuance of millions of shares of stock. The lawsuit makes additional allegations against Mr. McManus and Mr. Deitsch, including that Mr. McManus acted as a broker without SEC registration and defrauded at least one investor by making false statements about the Company, that Mr. Deitsch engaged in manipulative trades of the Company’s stock by offering to pay more for shares he was purchasing than the amount the seller was willing to take, and that Mr. Deitsch failed to make required public filings with the SEC. The lawsuit seeks both injunctive and monetary relief. On May 29, 2019 (following each of the defendants filing motions to dismiss), the SEC filed a First Amended Complaint which generally alleged the same conduct as its original Complaint, but accounted for certain guidance provided by the United States Supreme Court in a case that had been recently decided. Each of the defendants then moved to dismiss the SEC’s First Amended Complaint. On March 31, 2020, the Court entered an Order granting in part and denying in part the various motions to dismiss. Following that Order, the SEC filed a Second Amended Complaint (the operative pleading) and the defendants have filed their answers which generally deny liability. At this time, discovery is closed and the SEC has indicated an intent to file a summary judgment motion regarding certain non-fraud claims asserted in its Second Amended Complaint. The defendants have opposed the SEC’s request to file such motion(s). The Court conducted a hearing on February 23, 2021 and set an initial briefing schedule for the SEC’s Motion for Partial Summary Judgment wherein the Plaintiffs’ Motion for Partial Summary Judgment was due on April 5, 2021, the Defendants’ Consolidated (i.e., collectively, Nutra Pharma Corporation, Erik “Rik” Deitsch, and Sean McManus) Response Brief to the SEC’s Motion was due May 3, 2021, and the Plaintiffs’ Reply Brief was due on May 19, 2021. On March 23, 2021, the Plaintiff filed a Motion for Extension of Time to file the Motion for Partial Summary Judgment. On April 9, 2021, the Plaintiff filed a Motion for Partial Summary Judgment, Defendants’ filed a Memorandum of Law in Opposition to Plaintiff’s Motion on May 7, 2021, and Plaintiff filed its Reply brief on May 21, 2021. At this time the Court has not ruled on the pending Motion. The Company disputes the allegations in this lawsuit and continues to vigorously defend against the SEC’s claims. Mr. Deitsch and Mr. McManus have similarly defended the lawsuit since its filing and each contest liability. The Company does not believe that it engaged in any fraudulent activity or made any material misrepresentations concerning the Company and/or its products. |
Subsequent Events
Subsequent Events | 3 Months Ended |
Mar. 31, 2020 | |
Subsequent Events [Abstract] | |
Subsequent Events | 12. SUBSEQUENT EVENTS Convertible Notes Payable During August 2020, the convertible promissory notes of $38,500 was amended with additional original issuance discount of $7,550 due February 2021. During October 2020, the convertible promissory note of $16,500 was amended with additional original issuance discount (OID) of $1,650 due April 2021.The Noteholders have the right to convert the note into shares of Common Stock at a conversion price of $0.0005. In connection with the issuance of amended convertible notes, the Company granted the following warrants at an exercise price of $0.001 per share. The warrants were valued using the Black-Scholes method and recorded as a debt discount. No warrants have been exercised. The gross proceeds of the notes were allocated to debt and warrants issued on a relative fair value basis. The debt discounts associated with the warrants and OID for $29,481 and $9,200, respectively, are amortized over the life of the notes. Number of Fair Value of Month of Month of Issuance Warrants Warrants Expiration August, 2020 92,100,000 $ 20,848 August, 2021 October, 2020 39,930,000 $ 8,633 October, 2022 Pursuant to the Note agreement in the amount up to $1,000,000 signed in February 2019, the principal balance of the note is $112,799 as of March 31, 2020. Proceeds in the amount of $ 128,937 Number of Fair Value of Date shares converted Debt Converted 2/25/2021 137,700,000 $ 1,500,930 3/3/2021 67,380,000 $ 599,682 4/26/2021 27,070,000 $ 192,197 6/1/2021 5,700,000 $ 35,340 6/24/2021 2,500,000 $ 16,250 During August 2020, we issued a convertible promissory note to an unrelated third party for a $22,000 with original issuance discount of $2,000. The Noteholder has the right to convert the note into shares of Common Stock at a fixed conversion price of $0.0005. The note is due August 2021. During July 2020, we issued a convertible promissory note to an unrelated third party for $20,900 with original issuance discount of $1,900. The Noteholder has the right to convert the note into shares of Common Stock at a fixed conversion price of $0.00052. The note was due January 2021. The Note is in default and negotiation of settlement. During August 2020, we issued a convertible promissory note to an unrelated third party for $5,500 with original issuance discount of $500. The Noteholder has the right to convert the note into shares of Common Stock at a fixed conversion price of $0.0005. The note was due February 2021. The Note is in default and negotiation of settlement. During October and November 2020, we issued convertible promissory notes to 3 unrelated third parties for $208,800 with original issuance discount of $19,800. The Noteholders have the right to convert the note into shares of Common Stock at a conversion price ranging from $0.00022 to $0.0005 per share. The notes were due in April and May 2021. The Notes are in default and negotiation of settlement. During November 2020, we issued a convertible promissory note to an unrelated third party for $139,150 with original issuance discount of $12,650. The Noteholder has the right to convert the note into shares of Common Stock at a fixed conversion price of $0.00055. The note is due November 2021. During November and December 2020, we issued two convertible promissory notes to unrelated third parties for a total of $57,500 with original issuance discount of $7,500. The notes are due one year from the execution and funding of the notes. The Noteholders have the right to convert the note into shares of Common Stock at a conversion price of $0.0008. In connection with the issuance of convertible notes, the Company granted the 71,875,000 warrants at an exercise price of $0.002 per share that expire one year from the date of issuance. The warrants are valued using the Black-Scholes method and recorded as a debt discount. No warrants have been exercised. The gross proceeds of the notes were allocated to debt and warrants issued on a relative fair value basis. The debt discounts associated with the warrants and OID for $30,417 and $7,500, respectively, are amortized over the life of the notes. During November 2020, the Note holder assigned $20,000 of the $75,900 convertible note restated in January 2019 to a third party. The third party subsequently received a total of 100,000,000 shares of our restricted common stock in satisfaction the $20,000 of the Note with a fair value of $140,000. At December 31, 2020, the balance of $55,900 remains outstanding. The note was due January 2021. The Note is in default and negotiation of settlement. During the first quarter of 2021, we issued convertible promissory notes to the unrelated third parties for a total of $717,667 with original issuance discount of $93,609. The Noteholders have the right to convert the note into shares of Common Stock at a conversion price ranging from $0.0003 to $0.002 per share. The notes are due one year from the execution and funding of the notes. During the second quarter of 2021, we issued convertible promissory notes to the unrelated third parties for a total of $864,225 with original issuance discount of $112,725. The Noteholders have the right to convert the note into shares of Common Stock at a conversion price ranging from $0.0008 to $0.002 per share. The notes are due one year from the execution and funding of the notes. During July 2021, we issued convertible promissory notes to the unrelated third parties for a total of $16,100 with original issuance discount of $2,100. The Noteholders have the right to convert the note into shares of Common Stock at a conversion price of $0.002 per share. The notes are due one year from the execution and funding of the notes. PPP Loan During May 2020, we entered into a two-year loan agreement with the U. S. Small Business Administration for a Payroll Protection Program (PPP) loan, for $64,895 with an annual interest rate of one percent (1%), with a term of twenty-four (24) months, whereby a portion of the loan proceeds have been used for certain labor costs, office rent costs and utilities, which may be subject to a loan forgiveness, pursuant to the terms of the SBA/PPP program. Economic Injury Disaster Loan During April and June 2020, the Company executed the standard loan documents required for securing a loan from the SBA under its Economic Injury Disaster Loan assistance program (the “EIDL Loan”) considering the impact of the COVID-19 pandemic on the Company’s business. Pursuant to the Loan Authorization and Agreement (the “SBA Loan Agreement”), the principal amount of the EIDL Loan was $150,000, with proceeds to be used for rent, payroll, utilities, accounting and legal expenses. Interest accrues at the rate of 3.75% per annum. Installment payments, including principal and interest, are due twenty-four months from the date of the SBA Loan Agreement in the amount of $731. The balance of principal and interest is payable over a 360 month period from the date of the SBA Loan Agreement. In connection therewith, the Company received a $5,000 advance, which does not have to be repaid. The SBA requires that the Company collateralize the loan to the maximum extent up to the loan amount. If business fixed assets do not “fully secure” the loan the lender may include trading assets (using 10% of current book value for the calculation), and must take available equity in the personal real estate (residential and investment) of the principals as collateral. Restatement of Promissory Notes During July 2020, the restated Note of $148,225 plus accrued interest of $18,701 was further restated. The new principal balance was $166,926 that carries interest at a rate of 2.0% monthly and was due January 2021. During February 2021, we issued 29,072,500 shares of common stock to satisfy the accrued interest of $23,258 with fair value of $343,056. The settlement of accrued interest resulted in a loss on settlement of debt in other income for $319,798. The principal balance of $166,926 was further restated. The restated balance is $183,619 with an original issuance discount of $16,693 and is due August 2021. Settlement of Convertible Promissory Notes During February through August 2018, we issued seven convertible promissory notes to an unrelated third party due one year from the execution dates. The principal balance of these Notes on March 31, 2020 was $553,301. During September 2020, the Note holder received a total of 107,133,333 shares of our restricted common stock in satisfaction of the principal balance of $22,000 and accrued interest of $10,140. During October 2020, the Note holder received a total of 107,817,770 shares of our restricted common stock in satisfaction of the principal balance of $22,000 and accrued interest of $10,345. During October 2020, the Note holder sold the remaining debt of $467,319 and accrued interest of $166,168 for $250,000 to a non-related party. Number of Fair Value of Date shares converted Debt Converted 9/21/2020 107,133,333 $ 171,413 10/5/2020 107,817,770 64,691 During March 2021, in connection with this settlement of the $6,000 of the Note of $11,000 originated in November 2018, we issued 11,000,000 shares of common stocks in satisfaction of $6,000 of the Note with a fair value of $104,500 and made a repayment of $5,000 in cash. The settlement resulted in a loss on settlement of debt in other expense for $98,500. During April 2021, in connection with this settlement of the remaining balance of $8,500 of the Note of $12,000 originated in December 2018, we issued 2,000,000 shares of common stocks in satisfaction of $4,000 of the Note with a fair value of $15,200 and made a repayment of $4,500 in cash. The settlement resulted in a loss on settlement of debt in other expense for $11,200. Settlement of a Related-Party Note During June 2020, the Note of $14,400 with original issuance discount of $2,400 to a related party amended in December 2018 was settled with cash payment of $14,400 and 5,000,000 shares of common stocks. The shares were valued at fair value of $3,000. Common Stock Issued for Default Payments During July 2020, we issued a total of 1,000,000 restricted shares to a Note holder due to the default on repayments of the promissory note of $22,000 originated in December 2019. The shares were valued at fair value of $700. During September 2020, we issued a total of 10,000,000 restricted shares to a Note holder due to the default on repayments of the promissory note of $333,543 plus accrued interest amended in September 2019. The shares were valued at fair value of $6,000. During October 2020, we issued a total of 1,500,000 restricted shares to a Note holder due to the default on repayments of the promissory note of $84,000 amended in March 2020. The shares were valued at fair value of $900. During January 2021, we issued a total of 25,000,000 restricted shares to a Note holder due to the default on repayments of the promissory note of $166,926 amended in July 2020. The shares were valued at fair value of $107,500. Common Stock Issued for Consulting Service During June 2021, the Company signed an agreement with a consultant for services for six months for which the Company is to issue 30,000,000 shares of the Company’s restricted common stock. 5,000,000 of the shares were issued upon execution of the agreement and 5,000,000 shares will be issued every 30 days through November 2021. The compensation charge will be amortized over the term of the agreement. Convertible notes receivable On March 10, 2021, we purchased a convertible note from an unrelated third party for a total of $26,950 with original issuance discount of $2,450. The note is convertible into common shares for $0.01 per common share and mature on March 10, 2022. On May 20, 2021, we purchased a convertible note from an unrelated third party for a total of $145,200 with original issuance discount of $13,200. The note is convertible into common shares for $0.01 per common share and mature on May 20, 2022. |
Basis of Presentation and Sum_2
Basis of Presentation and Summary of Significant Accounting Policies (Policies) | 3 Months Ended |
Mar. 31, 2020 | |
Accounting Policies [Abstract] | |
Organization | Organization Nutra Pharma Corp. (“Nutra Pharma”), is a holding company that owns intellectual property and operates in the biotechnology industry. Nutra Pharma was incorporated under the laws of the state of California on February 1, 2000, under the original name of Exotic-Bird.com. Through its wholly-owned subsidiary, ReceptoPharm, Inc. (“ReceptoPharm”), Nutra Pharma conducts drug discovery research and development activities. In October 2009, Nutra Pharma launched its first consumer product called Cobroxin ® ® ® |
Basis of Presentation and Consolidation | Basis of Presentation and Consolidation The Unaudited Condensed Consolidated Financial Statements and notes are presented in accordance with the rules and regulations of the Securities and Exchange Commission and do not contain certain information included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019. In the opinion of management, all adjustments considered necessary for a fair presentation have been included and are of a normal, recurring nature. Interim results are not necessarily indicative of results for a full year. Therefore, the interim Unaudited Condensed Consolidated Financial Statements should be read in conjunction with the Consolidated Financial Statements and notes thereto contained in the Company’s Annual Report on Form 10-K. The accompanying Unaudited Condensed Consolidated Financial Statements include the results of Nutra Pharma and its wholly-owned subsidiaries Designer Diagnostics Inc. and ReceptoPharm (collectively “the Company”, “us”, “we” or “our”). We operate as one reportable segment. Designer Diagnostics Inc. has been inactive since June 2011. All intercompany transactions and balances have been eliminated in consolidation. |
Liquidity and Going Concern | Liquidity and Going Concern Our Unaudited Condensed Consolidated Financial Statements are presented on a going concern basis, which contemplate the realization of assets and satisfaction of liabilities in the normal course of business. We have experienced recurring, significant losses from operations, and have an accumulated deficit of $65,681,240 at March 31, 2020. In addition, we have a significant amount of indebtedness in default, a working capital deficit of $8,866,563 and a stockholders’ deficit of $8,928,291 at March 31, 2020. There is substantial doubt regarding our ability to continue as a going concern which is contingent upon our ability to secure additional financing, increase ownership equity and attain profitable operations. In addition, our ability to continue as a going concern must be considered in light of the problems, expenses and complications frequently encountered in established markets and the competitive environment in which we operate. We do not have sufficient cash to sustain our operations for a period of twelve months from the issuance date of this report and will require additional financing in order to execute our operating plan and continue as a going concern. Since our sales are not currently adequate to fund our operations, we continue to rely principally on debt and equity funding; however, proceeds from such funding have not been sufficient to execute our business plan. Our plan is to attempt to secure adequate funding until sales of our pain products are adequate to fund our operations. We cannot predict whether additional financing will be available, and/or whether any such funding will be in the form of equity, debt, or another form. In the event that these financing sources do not materialize, or if we are unsuccessful in increasing our revenues and profits, we will be unable to implement our current plans for expansion, repay our obligations as they become due and continue as a going concern. The accompanying Unaudited Condensed Consolidated Financial Statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern. |
Impact of COVID-19 on our Operations | Impact of COVID-19 on our Operations The ramifications of the outbreak of the novel strain of COVID-19, reported to have started in December 2019 and spread globally, are filled with uncertainty and changing quickly. Our operations have continued during the COVID-19 pandemic and we have not had significant disruption. Beginning in June 2020, the Company experienced a delay in retail rollout as a downstream implication of the slowing economy. We also closed our Coral Springs office in effort to save money. During May 2020, we received approval from SBA to fund our request for a PPP loan for $64,895. We used the proceeds primarily for payroll costs. We expect forgiveness of this loan under the current terms of requirement by the SBA. During April and June 2020, we obtained the loan in the amount of $150,000 from SBA under its Economic Injury Disaster Loan assistance program. We used the proceeds primarily for rent, payroll, utilities, accounting and legal expenses (See Note 12). The Company is operating in a rapidly changing environment so the extent to which COVID-19 impacts its business, operations and financial results from this point forward will depend on numerous evolving factors that the Company cannot accurately predict. Those factors include the following: the duration and scope of the pandemic; governmental, business and individuals’ actions that have been and continue to be taken in response to the pandemic; and the distribution of testing and a vaccine. |
Use of Estimates | Use of Estimates The accompanying Unaudited Condensed Consolidated Financial Statements are prepared in accordance with accounting principles generally accepted in the United States of America which require management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense. Significant estimates include our ability to continue as a going concern, the recoverability of inventories and long-lived assets, the recoverability of amounts due from officer, the valuation of stock-based compensation and certain debt and derivative liabilities, recognition of loss contingencies and deferred tax valuation allowances. Actual results could differ from those estimates. Changes in facts and circumstances may result in revised estimates, which would be recorded in the period in which they become known. |
Revenue from Contracts with Customers | Revenue from Contracts with Customers The Company accounts for revenue from contracts with customers in accordance with Financial Accounting Standard Board (“FASB”) Accounting Standard Codification (“ASC”) Topic 606, Revenue from Contracts with Customers Our revenues are primarily derived from customer orders for the purchase of our products. We recognize revenues as performance obligations are fulfilled upon shipment of products. We record revenues net of promotions and discounts. For certain product sales to a distributor, we record revenue including a portion of the cash proceeds that is remitted back to the distributor. |
Accounting for Shipping and Handling Costs | Accounting for Shipping and Handling Costs We account for shipping and handling as fulfillment activities and record amounts billed to customers as revenue and the related shipping and handling costs as cost of sales. |
Accounts Receivable and Allowance for Doubtful Accounts | Accounts Receivable and Allowance for Doubtful Accounts We grant credit without collateral to our customers based on our evaluation of a particular customer’s credit worthiness. Accounts receivable are due 30 days after the issuance of the invoice. In addition, allowances for doubtful accounts are maintained for potential credit losses based on the age of the accounts receivable and the results of periodic credit evaluations of our customers’ financial condition. Accounts receivable are written off after collection efforts have been deemed to be unsuccessful. Accounts written off as uncollectible are deducted from the allowance for doubtful accounts, while subsequent recoveries are netted against the provision for doubtful accounts expense. We generally do not charge interest on accounts receivable. We use third party payment processors and are required to maintain reserve balances, which are included in accounts receivable. Accounts receivable are stated at estimated net realizable value. Accounts receivable are comprised of balances due from customers net of estimated allowances for uncollectible accounts. No allowance for doubtful account is deemed to be required at March 31, 2020 and December 31, 2019. |
Inventories | Inventories Inventories, which are stated at the lower of average cost or net realizable value, consist of packaging materials, finished products, and raw venom that is utilized to make the API (active pharmaceutical ingredient). The raw unprocessed venom has an indefinite life for use. Commencing on October 1, 2019, we classify inventory as short-term or long-term inventory based on timing of when it is expected to be consumed. The Company regularly reviews inventory quantities on hand. If necessary, it records a net realizable value adjustment for excess and obsolete inventory based primarily on its estimates of product demand and production requirements. Write-downs are charged to cost of goods sold. We performed an evaluation of our inventory and related accounts at March 31, 2020 and December 31, 2019, and increased the reserve on supplier advances for future venom purchases included in prepaid expenses and other current assets by $0 and $23,948, respectively. At both March 31, 2020 and December 31, 2019, the total valuation allowance for prepaid venom was $224,859. |
Financial Instruments and Concentration of Credit Risk | Financial Instruments and Concentration of Credit Risk Our financial instruments include cash, accounts receivable, accounts payable, accrued expenses, loans payable, due to officers and derivative financial instruments. Other than certain warrant and convertible instruments (derivative financial instruments) and liabilities to related parties (for which it was impracticable to estimate fair value due to uncertainty as to when they will be satisfied and a lack of similar type transactions in the marketplace), we believe the carrying values of our financial instruments approximate their fair values because they are short term in nature or payable on demand. Our derivative financial instruments are carried at a measured fair value. Balances in various cash accounts may at times exceed federally insured limits. We have not experienced any losses in such accounts. We do not hold or issue financial instruments for trading purposes. In addition, for the three months ended March 31, 2020, there was one customer that accounted for 59% of the total revenues. For the three months ended March 31, 2019, there were two customers that accounted for 61% and 17% of the total revenues, respectively. As of March 31, 2020 and December 31, 2019, 100% of the accounts receivable balance are reserves due from two payment processors. |
Operating Lease Right-of-Use Asset and Liability | Operating Lease Right-of-Use Asset and Liability In February 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-02, Leases The Company elected the package of practical expedients as permitted under the transition guidance, which allowed us: (1) to carry forward the historical lease classification; (2) not to reassess whether expired or existing contracts are or contain leases; and, (3) not to reassess the treatment of initial direct costs for existing leases. In accordance with ASC Topic 842, at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset, whether we obtain the right to substantially all the economic benefit from the use of the asset, and whether we have the right to direct the use of the asset. Leases with a term greater than one year are recognized on the balance sheet as ROU assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less under practical expedient in paragraph ASC 842-20-25-2. Lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected lease term. The implicit rate within our operating leases are generally not determinable and, therefore, the Company uses the incremental borrowing rate at the lease commencement date to determine the present value of lease payments. The determination of the Company’s incremental borrowing rate requires judgment. The Company determines the incremental borrowing rate for each lease using our estimated borrowing rate. |
Derivative Financial Instruments | Derivative Financial Instruments Management evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to income. For option-based simple derivative financial instruments, the Company uses the Black-Scholes option-pricing model to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date. We do not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. |
Convertible Debt | Convertible Debt For convertible debt that does not contain an embedded derivative that requires bifurcation, the conversion feature is evaluated to determine if the rate of conversion is below market value and should be categorized as a beneficial conversion feature (“BCF”). A BCF related to debt is recorded by the Company as a debt discount and with the offset recorded to equity. The related convertible debt is recorded net of the discount for the BCF. The discount is amortized as additional interest expense over the term of the debt with the resulting debt discount being accreted over the term of the note. |
The Fair Value Measurement Option | The Fair Value Measurement Option We have elected the fair value measurement option for convertible debt with embedded derivatives that require bifurcation, and record the entire hybrid financing instrument at fair value under the guidance of ASC Topic 815, Derivatives and Hedging |
Derivative Accounting for Convertible Debt and Options and Warrants | Derivative Accounting for Convertible Debt and Options and Warrants The Company evaluated the terms and conditions of the convertible debt under the guidance of ASC Topic 815, Derivatives and Hedging Embedded Derivatives |
Property and Equipment | Property and Equipment Property and equipment is recorded at cost. Expenditures for major improvements and additions are added to property and equipment, while replacements, maintenance and repairs which do not extend the useful lives are expensed. Depreciation is computed using the straight-line method over the estimated useful lives of the assets of 3 – 7 years. |
Long-Lived Assets | Long-Lived Assets The carrying value of long-lived assets is reviewed annually and on a regular basis for the existence of facts and circumstances that may suggest impairment. If indicators of impairment are present, we determine whether the sum of the estimated undiscounted future cash flows attributable to the long-lived asset in question is less than its carrying amount. If less, we measure the amount of the impairment based on the amount that the carrying value of the impaired asset exceeds the discounted cash flows expected to result from the use and eventual disposal of the impaired assets. |
Income Taxes | Income Taxes The Company recorded no income tax expense for the three months ended March 31, 2020 and 2019 because the estimated annual effective tax rate was zero. As of March 31, 2020, the Company continues to provide a valuation allowance against its net deferred tax assets since the Company believes it is more likely than not that its deferred tax assets will not be realized. |
Stock-Based Compensation | Stock-Based Compensation We account for stock-based compensation in accordance with FASB ASC Topic 718, Stock Compensation |
Net Income (Loss) Per Share | Net Income (Loss) Per Share Net income (loss) per share is calculated in accordance with FASB ASC Topic 260, Earnings per Share Three Months Ended March 31, 2020 2019 Basic and diluted numerator: Net income (loss) - basic $ 2,183,044 $ (400,443 ) Effect of dilutive securities: Change in fair value of convertible notes (2,854,140 ) - Interest on convertible debt 8,735 - Net loss - diluted $ (662,361 ) $ (400,443 ) Basic and diluted denominator: Weighted-average common shares outstanding - basic 6,272,328,529 4,112,446,110 Effect of dilutive securities: Convertible debt 6,020,875,493 - Weighted-average common shares outstanding - diluted (1) 12,293,204,022 4,112,446,110 Net income (loss) per share - basic and diluted $ (0.00 ) $ (0.00 ) (1) Includes potential common shares that are in excess of authorized shares. As of March 31, 2020 and 2019, the following items were not included in dilutive loss as the effect is anti-dilutive: March 31, 2020 March 31, 2019 Options and warrants 46,500,000 122,600,000 Convertible notes payable at fair value - 6,972,376,110 Convertible notes payable - 1,237,780,833 Total 46,500,000 8,332,756,943 |
Recent Accounting Pronouncements | Recent Accounting Pronouncements In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes In August 2020, the FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity All other newly issued accounting pronouncements but not yet effective have been deemed either immaterial or not applicable. |
Basis of Presentation and Sum_3
Basis of Presentation and Summary of Significant Accounting Policies (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Accounting Policies [Abstract] | |
Schedule of Earnings Per Share, Basic and Diluted | Three Months Ended March 31, 2020 2019 Basic and diluted numerator: Net income (loss) - basic $ 2,183,044 $ (400,443 ) Effect of dilutive securities: Change in fair value of convertible notes (2,854,140 ) - Interest on convertible debt 8,735 - Net loss - diluted $ (662,361 ) $ (400,443 ) Basic and diluted denominator: Weighted-average common shares outstanding - basic 6,272,328,529 4,112,446,110 Effect of dilutive securities: Convertible debt 6,020,875,493 - Weighted-average common shares outstanding - diluted (1) 12,293,204,022 4,112,446,110 Net income (loss) per share - basic and diluted $ (0.00 ) $ (0.00 ) |
Schedule of Antidilutive Securities Excluded from Computation of Net Loss Per Share | As of March 31, 2020 and 2019, the following items were not included in dilutive loss as the effect is anti-dilutive: March 31, 2020 March 31, 2019 Options and warrants 46,500,000 122,600,000 Convertible notes payable at fair value - 6,972,376,110 Convertible notes payable - 1,237,780,833 Total 46,500,000 8,332,756,943 |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Summary of Financial Instruments Measured at Fair Value | The following table summarizes our financial instruments measured at fair value at March 31, 2020 and December 31, 2019: Fair Value Measurements at March 31, 2020 Liabilities: Total Level 1 Level 2 Level 3 Warrant liability $ 866 $ - $ - $ 866 Derivative liabilities $ 1,145,655 $ - $ - $ 1,145,655 Convertible notes at fair value $ 2,562,049 $ - $ - $ 2,562,049 Fair Value Measurements at December 31, 2019 Liabilities: Total Level 1 Level 2 Level 3 Warrant liability $ 1,411 $ - $ - $ 1,411 Derivative liabilities $ 834,457 $ - $ - $ 834,457 Convertible notes at fair value $ 5,814,047 $ - $ - $ 5,814,047 |
Summary of Changes in Fair Value Measurements Using Significant Unobservable Inputs | The following table shows the changes in fair value measurements for the warrant liability using significant unobservable inputs (Level 3) during the three months ended March 31, 2020 and the year ended December 31, 2019: Description March 31, 2020 December 31, 2019 Beginning balance $ 1411 $ 1,468 Total gain included in earnings (1) (545 ) (57 ) Ending balance $ 866 $ 1,411 (1) The gain related to the revaluation of our warrant liability is included in “Change in fair value of convertible notes and derivatives” in the accompanying consolidated statement of operations. |
Summary of Assumptions and the Significant Terms | The following table summarizes assumptions and the significant terms of the convertible notes for which the entire hybrid instrument is recorded at fair value at March 31, 2020 and December 31, 2019: Conversion Price - Lower of Fixed Debenture Face Interest Default Discount Anti-Dilution % of stock price for look-back period Look-back March 31, 2020 $ 1,084,629 8%-10% 20%-24% N/A $0.00030-$0.00040 50%-60% 3 to 25 Days December 31, 2019 $ 1,244,204 8%-10% 20%-24% N/A $0.00010-$0.000293 50%-60% 3 to 25 Days |
Convertible Notes Payable [Member] | |
Summary of Changes in Fair Value Measurements Using Significant Unobservable Inputs | The following table shows the changes in fair value measurements for the convertible notes at fair value using significant unobservable inputs (Level 3) during the three months ended March 31, 2020 and the year ended December 31, 2019: Description March 31, 2020 December 31, 2019 Beginning balance $ 5,814,047 $ 1,156,341 Purchases and issuances 15,425 688,274 Day one loss on value of hybrid instrument (1) 18,181 926,109 (Gain) loss from change in fair value (1) (2,871,776 ) 3,423,935 Debt discount 11,172 (22,344 ) Settlement through issuance of common stock - (83,268 Conversion to common stock (425,000 ) (275,000 ) Ending balance $ 2,562,049 $ 5,814,047 (1) The (gains) losses related to the valuation of the convertible notes are included in “Change in fair value of convertible notes and derivatives” in the accompanying consolidated statement of operations. |
Inventories (Tables)
Inventories (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Inventory Disclosure [Abstract] | |
Schedule of Inventories | At March 31, 2020 and December 31, 2019, inventories were as follows: March 31, 2020 December 31, 2019 Raw Materials $ 65,568 $ 52,183 Finished Goods 6,624 8,177 Total Inventories 72,192 60,360 Less: Long-term inventory (65,568 ) (52,183 ) Current portion $ 6,624 $ 8,177 |
Property and Equipment (Tables)
Property and Equipment (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Property, Plant and Equipment [Abstract] | |
Schedule of Property and Equipment | Property and equipment consists of the following at March 31, 2020 and December 31, 2019: March 31, 2020 December 31, 2019 Computer equipment $ 25,120 $ 25,120 Furniture and fixtures 34,757 34,757 Lab equipment 53,711 53,711 Telephone equipment 12,421 12,421 Office equipment – other 16,856 16,856 Leasehold improvements 73,168 73,168 Total 216,033 216,033 Less: Accumulated depreciation (209,982 ) (209,270 ) Property and equipment, net $ 6,051 $ 6,763 |
Debts (Tables)
Debts (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Debt Disclosure [Abstract] | |
Schedule of Debt | Debts consist of the following at March 31, 2020 and December 31, 2019: March 31, 2020 December 31, 2019 Note payable– Related Party (1) $ 14,400 $ 14,400 Notes payable – Unrelated third parties (Net of discount of $19,947 and $8,921, respectively) (2) 1,394,693 1,385,163 Convertible notes payable – Unrelated third parties (Net of discount of $15,893 and $17,370, respectively) (3) 899,407 872,256 Convertible notes payable, at fair value (Net of discount of $11,172 and $22,344, respectively) (4) 2,562,049 5,814,047 Other advances from an unrelated third party (5) 200,000 175,000 Ending balances 5,070,549 8,260,866 Less: Long-term portion-Convertible Notes payable-Unrelated third parties (225,597 ) (907,912 ) Current portion $ 4,844,952 $ 7,352,954 (1) During 2010 we borrowed $200,000 from one of our directors. Under the terms of the loan agreement, this loan was expected to be repaid in nine months to a year from the date of the loan along with interest calculated at 10% for the first month plus 12% after 30 days from funding. We are in default regarding this loan. The loan is under personal guarantee by Mr. Deitsch. We repaid principal balance in full as of December 31, 2016. At March 31, 2020 and December 31, 2019, we owed this director accrued interest of $164,276 and $159,555. The interest expense for the three months ended March 31, 2020 and 2019 was $4,721 and $4,196. In December 2017, we issued a promissory note to a related party in the amount of $12,000 with original issuance discount of $2,000. The note was amended in December 2018 with original issuance discount of $2,400 and was due in twelve months from the execution and funding of the note. At March 31, 2020 and December 31, 2019, the principal balance of the loan is $14,400. The Note was settled in June 2020. (2) At March 31, 2020 and December 31, 2019, the balance of $1,394,693 and $1,385,163 net of discount of $19,947 and $8,921, respectively, consisted of the following loans: ● In August 2016, we issued two Promissory Notes for a total of $200,000 ($100,000 each) to a company owned by a former director of the Company. The notes carry interest at 12% annually and were due on the date that was six-months from the execution and funding of the note. Upon default in February 2017, the Notes became convertible at $0.008 per share. During March 2017, we repaid principal balance of $6,365. During April 2017, the Notes with accrued interest were restated. The restated principal balance of $201,818 bears interest at 12% annually and was due October 12, 2017. During June 2017, we repaid principal balance of $8,844. The loan was reclassified to notes payable – unrelated third parties after the director resigned in March 2018. At December 31, 2018, we owed principal balance of $192,974, and accrued interest of $40,033. The principal balance of $101,818 and accrued interest of $21,023 were settled on February 15, 2019 for $104,000 with scheduled payments through May 1, 2020 (See Note 12) ● On August 2, 2011 under a settlement agreement with Liquid Packaging Resources, Inc. (“LPR”), we agreed to pay LPR a total of $350,000 in monthly installments of $50,000 beginning August 15, 2011 and ending on February 15, 2012. This settlement amount was recorded as general and administrative expenses on the date of the settlement. We did not make the December 2011 or January 2012 payments and on January 26, 2012, we signed the first amendment to the settlement agreement where we agreed to pay $175,000, which was the balance outstanding at December 31, 2011(this includes a $25,000 penalty for non-payment). We repaid $25,000 during the three months ended March 31, 2012. We did not make all of the payments under such amendment and as a result pursuant to the original settlement agreement, LPR had the right to sell 142,858 shares (5,714,326 shares pre reverse stock split) of our free trading stock held in escrow by their attorney and receive cash settlements for a total amount of $450,000 (the initial $350,000 plus total default penalties of $100,000). The $100,000 penalty was expensed during 2012. LPR sold the note to Southridge Partners, LLP (“Southridge”) for consideration of $281,772 in June 2012. In August 2013 the debt of $281,772 reverted back to LPR. ● At December 31, 2012, we owed University Centre West Ltd. approximately $55,410 for rent, which was assigned and sold to Southridge, and it is currently outstanding and carries no interest. ● In April 2016, we issued a promissory note to an unrelated third party in the amount of $10,000 bearing interest at 10% annually. The note was due in one year from the execution and funding of the note. The note is in default and negotiation of settlement. At March 31, 2020 and December 31, 2019, the accrued interest is $4,006 and $3,755, respectively. ● In May 2016, the Company issued a promissory note to an unrelated third party in the amount of $75,000 bearing monthly interest at a rate of 2%. The note was due in six months from the execution and funding of the note. During April 2017, we accepted the offer of a settlement to issue 5,000,000 common shares as a repayment of $25,000. The note is in default and in negotiation of settlement. At March 31, 2020 and December 31, 2019, the outstanding principal balance is $50,000 and accrued interest is $53,001 and $49,967, respectively. ● In June 2016, the Company issued a promissory note to an unrelated third party in the amount of $50,000 bearing monthly interest at a rate of 2%. The note was due in six months from the execution and funding of the note. The note is in default and negotiation of settlement. At March 31, 2020 and December 31, 2019, the outstanding principal balance is $50,000 and accrued interest is $46,200 and $43,166, respectively. ● In August 2016, we issued a promissory note to an unrelated third party in the amount of $150,000 bearing monthly interest at a rate of 2.5%. The note was due in six months from the execution and funding of the note. During April 2017, the note with accrued interest was restated. The restated principal balance of $180,250 bears monthly interest at a rate of 2.5% and was due October 20, 2017. During January 2018, the note with accrued interest was restated. The restated principal balance of $220,506 bears monthly interest at a rate of 2.5% and was due July 12, 2018. In connection with this restated note, we issued 2,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $2,765 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Amortization for the debt discount for the year ended December 31, 2018 was $2,765. During July 2018, we issued 5,000,000 restricted shares due to the default on repayment of the promissory note of $220,506 restated in January 2018. The shares were valued at fair value of $5,500. During December 2018, the note with accrued interest was restated. The restated principal balance of $282,983 bears monthly interest at a rate of 2.0% and was due June 17, 2019. In connection with this restated note, we issued 10,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $3,945 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Amortization for this debt discount for the years ended December 31, 2019 and 2018 was $3,616 and $329, respectively. During September 2019, the notes of $282,983 plus accrued interest amended in December 2018 were restated. The restated principal balance of $333,543 were due September 2020. In connection with this restated note, we issued 20,000,000 shares of our common stock. The common stock was valued at $5,895 and recorded as a debt discount that was amortized over the life of the note. Amortization for this debt discount for the year ended December 31, 2019 was $1,474 and debt discount at December 31, 2019 is $4,421. Amortization for this debt discount for the three months ended March 31, 2020 was $1,474 and debt discount at March 31, 2020 is $2,947. The Note is in default and negotiation of settlement. At March 31, 2020 and December 31, 2019, the principal balance is $333,543, and the accrued interest is $45,362 and $25,127, respectively. ● On September 26, 2016, we issued a promissory note to an unrelated third party in the amount of $75,000 bearing interest at 10% annually. The note was due in one year from the execution and funding of the note. In March 2018, $15,000 of the principal balance of the note was assigned to an unrelated third party and is in negotiation of settlement. In January 2019, the remaining principal balance of $60,000 and accrued interest of $15,900 was restated in the form of a Convertible Note (See Note 6(4)). At March 31, 2020 and December 31, 2019, the principal balance outstanding is $15,000, and the accrued interest is $1,371. ● In October 2016, we issued a promissory note to an unrelated third party in the amount of $50,000 bearing monthly interest at a rate of 2%. The note was due in six months from the execution and funding of the note. The note is in default and in negotiation of settlement. At March 31, 2020 and December 31, 2019, the accrued interest is $42,500 and $39,466, respectively. ● In June 2017, we issued a promissory note to an unrelated third party in the amount of $12,500 bearing interest at 10% annually. The note was due in one year from the execution and funding of the note. The note is in default and in negotiation of settlement. At March 31, 2020 and December 31, 2019, the accrued interest is $3,528 and $3,212, respectively. ● During July 2017, we received a loan for a total of $200,000 from an unrelated third party. The loan was repaid through scheduled payments through August 2017 along with interest on average 15% annum. We have recorded loan costs in the amount of $5,500 for the loan origination fees paid at inception date. The debt discount was fully amortized as of December 31, 2018. During June 2018, the loan was settled with two unrelated third parties for $130,401 and $40,000, respectively, with the monthly scheduled repayments of approximately $5,000 and $2,000 per month to each unrelated party through July 2020. We recorded a gain on settlement of debt in other income for $20,927 in June 2018. The Company repaid a total of $34,976 and $42,698 during 2018 and 2019, respectively. The Company repaid $12,694 during the three months ended March 31, 2020. At March 31, 2020 and December 31, 2019, the principal balance is $80,034 and $92,728, respectively. The portion of settlement of $130,401 was repaid in full in April 2021. The remaining balance of $33,874 is in default and negotiation of settlement. ● In July 2017, we issued a promissory note to an unrelated third party in the amount of $50,000 with original issue discount of $10,000. The note was due in six months from the execution and funding of the note. The original issuance discount was fully amortized as of March 31, 2018. The note is in default and in negotiation of settlement. At March 31, 2020 and December 31, 2019, the principal balance of the note is $50,000. ● In September 2017, we issued a promissory note to an unrelated third party in the amount of $36,000 with original issue discount of $6,000. During September 2018 and 2019, the Note was amended with original issuance discount of $6,000 due in September 2019 and 2020. The Note was further restated in September 2020. The restated principal balance was $33,000 with the original issuance discount of $3,000 and was due March 2021. The original issue discount is amortized over the term of the loan. Amortization for the debt discount for the years ended 2019 and 2018 was $7,500 and $4,000, respectively. Repayments of $1,500, $7,000 and $5,000 have been made during 2017, 2018 and 2019, respectively. Additionally, repayment of $2,000 was made during the three months ended March 31, 2020. The Note is under personal guarantee by Mr. Deitsch. At March 31, 2020 and December 31, 2019, the principal balance of the note is $29,500 and $30,000, net of debt discount of $3,000 and $4,500, respectively. During March 2021, the remaining balance of $30,000 was sold to an unrelated third party in the form of a convertible note at a fixed conversion price of $0.01 per share. The new note carries interest at 12% with scheduled monthly payments of $1,000 beginning in April 2021 through March 2024. ● In October 2017, we issued a promissory note to an unrelated third party in the amount of $50,000 with original issuance discount of $10,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $3,200 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. At December 31, 2017, the principal balance of the note is $60,000. Debt discount and original issuance discount were fully amortized as of December 31, 2018. During April 2018, we issued a total of 1,000,000 restricted shares to a Note holder due to the default on repayment. The shares were valued at fair value of $1,700. During April 2018, the Note was restated in the amount of $60,000 including the original issuance discount of $10,000 due October 2018. In connection with this restated note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $8,678 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discount and original issuance discount for a total of $18,678 have been fully amortized as of December 31, 2018. During November 2018, the Note was restated in the amount of $60,000 including the original issuance discount of $10,000 due May 2019. In connection with this restated note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $2,381 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Pursuant to the restatement of the Note, the Company agreed that the original issuance discount of $10,000 from the April 2018 Note would be paid to the lender upon execution of restated Note in November 2018. The settlement agreement executed in December 2018 provides that 10,000,000 shares are issued due to the late payment. The shares were valued at $3,000. During July 2019, payment of original issuance discount of $10,000 was made. During September 2019, we issued additional 10,000,000 restricted shares due to the late payment of the original issuance discount of $10,000. The shares were valued at fair value of $4,000. The restated Note in November 2018 and prior notes are all under personal guarantee by Mr. Deitsch. Amortization of debt discount and original issuance discount for the three months ended March 31, 2020 and 2019 was $0 and $4,127, respectively, for the restated Note in November 2018. The total debt discounts of $12,381 were fully amortized as of June 30, 2019. As of December 31, 2019, the amount due is $60,000. During January 2020, the Note of $60,000 and the Note of $76,076 (See Note 6(3)) plus accrued interest of $12,149 were combined and restated at a rate of 2.0% monthly due July 2020. At March 31, 2020, the restated principal balance and accrued interest was $148,225 and $7,710, respectively. The principal balance plus accrued interest was further restated in July 2020 and February 2021 and is due in August 2021(See Note 12). ● In November 2017, we issued a promissory note to an unrelated third party in the amount of $120,000 with original issuance discount of $20,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 10,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $5,600 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discounts were fully amortized as of December 31, 2018. 1,500,000 shares of common stocks were issued due to the default of repayments with a fair value of $2,250 in May 2018. During March 2020, $50,000 of the Note of $120,000 with original issuance discount of $20,000 originated in November 2017 was settled for 125,000,000 shares with a fair value of $87,500. We recorded a loss on settlement in other expense for $37,500 (See Note 7). An additional 46,000,000 shares with a fair value of $32,200 were issued due to the default on repayment of the promissory note. The remaining balance of $70,000 was restated with additional issuance discount of $14,000. The $84,000 due in September 2020 is in default and negotiation of further settlement. At March 31, 2020 and December 31, 2019, the principal balance of the loan is $70,000 and $120,000, net of discount of $14,000 and $0, respectively. ● In November 2017, we issued a promissory note to an unrelated third party in the amount of $18,000 with original issuance discount of $3,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $2,900 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discounts were fully amortized as of December 31, 2018. The note is in default and in negotiation of settlement. In September 2018, 7,000,000 shares of common stock were issued due to the default of repayments with a fair value of $5,600. At March 31, 2020 and December 31, 2019, the principal balance of the note is $18,000 and the accrued interest is $2,000. (3) At March 31, 2020 and December 31, 2019, the balance of $899,407 and $872,256 net of discount of $15,893 and $17,370, respectively, consisted of the following convertible loans: ● During July 2016, we issued a convertible note to an unrelated third party in the amount of $50,000 bearing monthly interest at a rate of 2.0% and convertible at $0.05 per share. During January 2017, the Note was restated with principal amount of $56,567 bearing monthly interest rate of 2.5%. The New Note of $56,567 was due on July 26, 2017 and convertible at $0.05 per share. During February 2018, the Notes with accrued interest of $65,600 was restated. The restated principal balance of $65,600 bears monthly interest at a rate of 2.5% and was due August 14, 2018. In connection with this restated note, we issued 1,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $4,035 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discount was fully amortized as of December 31, 2018. During August 2018, the Notes with accrued interest of $10,476 were restated. The restated principal balance of $76,076 bears monthly interest at a rate of 2.5% and was due February 2019. In connection with this restated note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $3,800 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Amortization of debt discount of $2,850 has been recorded as of December 31, 2018. The remaining debt discount of $950 was fully amortized during the three months ended March 31, 2019. The note is under personal guarantee by Mr. Deitsch. At December 31, 2019, the convertible note payable was recorded at $76,076 with accrued interest of $12,149. During January 2020, this Note and the Note of $60,000 amended in November 2018(See Note 6(2)) were combined and restated with principal balance of $148,225(See Note 12). ● In October 2017, we issued a promissory note to an unrelated third party in the amount of $60,000 with original issuance discount of $10,000 and a conversion option. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $3,300 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discounts were fully amortized as of December 31, 2018. The loan is in default and in negotiation of settlement. In April 2018, 1,000,000 shares of common stock were issued due to the default of repayments with a fair value of $1,500. At March 31, 2020 and December 31, 2019, the principal balance of the note is $60,000. ● During January through December 2018, we issued convertible notes payable to the 20 unrelated third parties for a total of $618,250 with original issue discount of $62,950. The notes are due in six months from the execution and funding of each note. The notes are convertible into shares of Company’s common stock at a conversion price ranging from $0.0003 to $0.001 per share. The difference between the conversion price and the fair value of the Company’s common stock on the date of issuance of the convertible notes resulted in a beneficial conversion feature in the amount of $249,113. In addition, upon the issuance of convertible notes, the Company issued 10,250,000 shares of common stock. The Company has recorded a debt discount in the amount of $6,542 to reflect the value of the common stock as a reduction to the carrying amount of the convertible debt and a corresponding increase to common stock and additional paid-in capital. The total discount of $255,655 and original issuance discount of $62,950 was amortized over the term of the debt. At December 31, 2018, the principal balance of the notes, net of discount of $28,421 was $589,829. During February 2019, we issued convertible notes payable of $70,000 with original issuance discount of $5,000. The notes were due in six months from the execution and funding of each note. The notes are convertible into shares of Company’s common stock at a conversion price of $0.0005 per share. During December 2019, $22,000 of the Note was amended to extend the maturity date to June 2020. In connection with the issuance and restatements of the notes, the Company granted the following warrants at an exercise price of $0.001 per share in 2019. The warrants were valued using the Black-Scholes method and recorded as a debt discount that was amortized over the life of the notes. The Notes were further restated in August and October 2020 and are currently in default and in negotiation of settlement. Month of Issuance Number of Warrants Fair Value of Warrants Month of Expiration February, 2019 110,000,000 $ 8,147 August, 2019 December, 2019 44,000,000 $ 7,370 August, 2020 During May 2019, we restated two convertible notes payable with additional original issue discount of $6,400 and issued 6,000,001 shares of common stock with a fair value of $1,800. The two restated notes were due in August 2019 and are in default. The total discount of $8,200 was amortized over the term of the notes. During November and December 2019, we issued two convertible promissory notes to two unrelated third parties for $159,500 with original issuance discount of $14,500. The notes were due six months from the execution and funding of each note. The Noteholder had the right to convert the note into shares of Common Stock at a fixed conversion price ranging from $0.0002 to$0.000275. The Notes are in default and negotiation of settlement. During 2019, repayments of $13,500 were made in cash to three of the Notes. Six of the Notes for a total of $87,100 were repaid in stocks as the part of settlement of issuances of 800,000,000 shares of common stocks during December 2019. Amortization for the year ended December 31, 2019 was $55,222. Additionally, $9,185 was amortized during the three months ended March 31, 2020. At December 31, 2019, the principal balance of the notes, net of discount of $17,370 is $736,180. Two of the above mentioned convertible notes payable for a total of $19,500 was settled in full in March and April 2021(See Note 12). During the three months ended March 31, 2020, we issued convertible notes payable of $101,750 with original issuance discount of $9,250. Amortization for this discount for the three months ended March 31, 2020 was $1,542. $33,000 of the notes were due in six months from the execution and funding of each note. $68,750 of the notes were due in one year from the execution and funding of each note. The notes are convertible into shares of Company’s common stock at a conversion price ranging from $0.002 to 0.0005 per share. All of the above mentioned convertible notes payable of $915,300 are in default and in negotiation of settlement. At March 31, 2020, the principal balance of the notes, net of discount of $15,893 is $839,407. (4) At March 31, 2020 and December 31, 2019, the balance of $2,562,049 and $5,814,047 net of discount of $11,172 and $22,344, respectively, consisted of the following convertible loans: ● On March 28, 2016, we signed an expansion agreement with Brewer and Associates Consulting, LLC (“B+A”) to the original consulting agreement dated on October 15, 2015 for consulting services for twelve months for a monthly fee of $7,000. To relieve our cash obligation of $36,000 per original agreement, we issued three convertible notes for a total of $120,000 which includes the fees due under the original agreement and the new monthly fees due under the expansion agreement. The $40,000 and $60,000 of the Notes were paid in full as of December 31, 2016 and December 31, 2017, respectively. The remaining balance of $20,000 Notes is in default and negotiation of settlement. The conversion price is equal to 55% of the average of the three lowest volume weighted average prices for the three consecutive trading days immediately prior to but not including the conversion date. At March 31, 2020 and December 31, 2019, the convertible notes payable with principal balance of $20,000, at fair value, were recorded at $50,687 and $56,373, respectively. ● During May 2017, we issued a Convertible Debenture in the amount of $64,000 to an unrelated third party. The note carries interest at 8% and was due on May 4, 2018, unless previously converted into shares of restricted common stock. We have accrued interest at default interest rate of 20% after the note’s maturity date. The Note holder has the right to convert the note into shares of Common Stock at a sixty percent (60%) of the lowest trading price of our restricted common stock for the twenty trading days preceding the conversion date. During November 2017, the Note holder made a conversion of our restricted common stocks satisfying the principal balance of $856 and penalty of $6,400 for a fair value of $21,399. During February 2018, the remaining balance of $63,144 with accrued interest and penalty of $12,442 was assigned and sold to three unrelated third parties. During June 2018, a Note holder made a conversion of 50,670,000 shares of our restricted common stock with a fair value of $70,938 in satisfaction of the balance of $34,060 plus accrued interest of $8,607. During December 2019, the principal balance of $16,752 with accrued interest of $3,232 assigned and sold to a third party was settled as the part of settlement of issuances of 800,000,000 shares of common stocks during December 2019. At March 31, 2020 and December 31, 2019, the remaining principal of $12,629 plus accrued interest of $10,413 and $9,782, at fair value, was recorded at $38,404 and $62,253. The remaining principal balance of the Note is in default. All of the convertible notes discussed below are with a single unrelated third party. ● During December 2016, we issued a Convertible Debenture to an unrelated third party in the amount of $110,000. The note carries interest at 12% and matured on September 8, 2017. Unless previously converted into shares of restricted common stock, the Note holder has the right to convert the note into shares of Common Stock at a sixty percent (60%) of the lowest trading prices of our restricted common stock for the twenty-five trading days preceding the conversion date. During June and July 2017, the Note holder made conversions of a total of 179,800,000 shares of stock satisfying the principal balance of $63,001 and accrued interest for a fair value of $298,575. During February 2018, the remaining balance of $46,999 with accrued interest of $2,820 was assigned and sold to an unrelated third party in the form of a Convertible Redeemable Note. As part of the debt sale, the Company entered into a settlement agreement with the original noteholder for a settlement of a default penalty of the original debt. During February and July, 2018, we issued a total of 105,157,409 shares of our restricted common stock to the original Note holder with a fair value of $147,220. At December 31, 2018, the Company owed additional shares to the original noteholder and recorded an accrual of $32,400 to account for the cost of the shares, and the shares were issued in January 2019. The new note of $49,819 carries interest at 8% and was due on February 13, 2019, unless previously converted into shares of restricted common stock. We have increased the outstanding principal due by 10% and accrued interest at default interest rate of 24% after the note’s maturity date. The Noteholder has the right to convert the note into shares of our restricted common stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five prior trading days including the conversion date. The conversion discount was further decreased to fifty percent due to the default on the Note. During September 2018, the Noteholder made a conversion of 52,244,433 shares of our restricted common stock with a fair value of $37,011 in satisfaction of principal balance of $15,000 and accrued interest in full. At March 31, 2020 and December 31, 2019, the convertible note payable with principal balance of $38,301, at fair value, was recorded at $103,311 and $246,819. ● During February 2018, we issued a convertible debenture in the amount of $200,000 to an unrelated third party. The note carries interest at 8% and was due in February 2019, unless previously converted into shares of restricted common stock. We have increased the outstanding principal due by 10% and accrued interest at default interest rate of 24% after the note’s maturity date. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. The conversion discount was further decreased to fifty percent due to the default on the Note. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $1,646,242. At March 31, 2020 and December 31, 2019, the convertible note payable with principal balance of $220,000, at fair value, was recorded at $591,197 and $1,412,175. The note carries additional $200,000 “Back-end Note” ($100,000 each) with the same terms as the original note. ● During April 2018, $65,000 of one of the $100,000 Back-end Note was funded. The note carries interest at 8% and was due in February 2019, unless previously converted into shares of restricted common stock. We have increased the outstanding principal due by 10% and accrued interest at default interest rate of 24% after the note’s maturity date. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. The conversion discount was further decreased to fifty percent due to the default on the Note. In connection with the issua |
Stockholders' Deficit (Tables)
Stockholders' Deficit (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Equity [Abstract] | |
Schedule of Common Stock Issued for Conversion of Debt | Number of Fair Value of Date shares converted Debt Converted 1/21/2020 250,000,000 $ 150,000 2/18/2020 250,000,000 $ 275,000 |
Stock Warrants (Tables)
Stock Warrants (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Share-based Payment Arrangement [Abstract] | |
Schedule of Warrants Issued | The warrants were valued using the Black-Scholes method and recorded as a debt discount and additional paid in capital. No warrants have been exercised. Month of Issuance Number of Warrants Fair Value of Warrants Month of Expiration February, 2019 110,000,000 $ 8,147 August, 2019 December, 2019 44,000,000 $ 7,370 August, 2020 |
Summary of Warrants Outstanding | A summary of warrants outstanding in conjunction with private placements of common stock were as follows during the three months ended March 31, 2020 and the year ended December 31, 2019: Number Of shares Weighted average exercise price Balance December 31, 2018 12,600,000 $ 0.026 Exercised - - Issued 154,000,000 0.001 Expired (114,100,000 ) 0.0027 Balance December 31, 2019 52,500,000 $ 0.0028 Exercised - - Issued - - Expired (6,000,000 ) 0.005 Balance March 31, 2020 46,500,000 $ 0.0026 |
Summary of Fixed Price Warrants Outstanding | The following table summarizes information about fixed-price warrants outstanding as of March 31, 2020 and December 31, 2019 : Exercise Price Weighted Average Number Outstanding Weighted Average Contractual Life Weighted Average Exercise Price March 31, 2020 $ 0.001-0.03 46,500,000 0.42 years $ 0.0026 December 31, 2019 $ 0.001-0.03 10,187,671 0.62 years $ 0.0028 |
Accrued Expenses (Tables)
Accrued Expenses (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Payables and Accruals [Abstract] | |
Schedule of Accrued Expenses | Accrued expenses consisted of the following: March 31, 2020 December 31, 2019 Accrued consulting fees $ 161,550 $ 161,550 Accrued settlement expenses 35,000 35,000 Accrued payroll taxes 179,911 167,906 Accrued interest 238,354 231,186 Accrued others 15,459 16,905 Total $ 630,274 $ 612,547 |
Prepaid Expenses (Tables)
Prepaid Expenses (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] | |
Schedule of Prepaid Expenses | Prepaid expenses and other current assets consist of the following: March 31, 2020 December 31, 2019 Supplier advances for future purchases $ 224,859 $ 224,859 Reserve for supplier advances (224,859 ) (224,859 ) Net supplier advances - - Prepaid professional fees 20,265 8,650 Deferred stock compensation 1,000 8,500 Total $ 21,265 $ 17,150 |
Commitments and Contingencies (
Commitments and Contingencies (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Commitments and Contingencies Disclosure [Abstract] | |
Schedule of Lease Cost and Balance Sheet Information | March 31, 2020 Lease cost Operating lease cost $ 22,255 Short-term lease cost 11,219 Total lease cost $ 33,474 Balance sheet information Operating ROU Assets $ 200,276 Operating lease obligations, current portion 75,588 Operating lease obligations, non-current portion 123,576 Total operating lease obligations $ 199,164 Weighted average remaining lease term (in years) – operating leases 2.42 Weighted average discount rate-operating leases 8 % Supplemental cash flow information related to leases were as follows, for the three months ended March 31, 2020: Cash paid for amounts included in the measurement of operating lease liabilities $ 32,437 |
Schedule of Future Minimum Payments Under Lease Agreements | Future minimum payments under these lease agreements are as follows: December 31, Total 2020(Remaining nine months) $ 66,339 2021 91,379 2022 62,274 Total future lease payments $ 219,992 Less imputed interest 20,828 Total $ 199,164 |
Subsequent Events (Tables)
Subsequent Events (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Schedule of Common Stock Issued for Conversion of Debt | Number of Fair Value of Date shares converted Debt Converted 1/21/2020 250,000,000 $ 150,000 2/18/2020 250,000,000 $ 275,000 |
Convertible Notes Payable [Member] | |
Summary of Warrants Issuance | Number of Fair Value of Month of Month of Issuance Warrants Warrants Expiration August, 2020 92,100,000 $ 20,848 August, 2021 October, 2020 39,930,000 $ 8,633 October, 2022 |
Schedule of Common Stock Issued for Conversion of Debt | Number of Fair Value of Date shares converted Debt Converted 2/25/2021 137,700,000 $ 1,500,930 3/3/2021 67,380,000 $ 599,682 4/26/2021 27,070,000 $ 192,197 6/1/2021 5,700,000 $ 35,340 6/24/2021 2,500,000 $ 16,250 |
Settlement of Convertible Promissory Notes [Member] | |
Schedule of Common Stock Issued for Conversion of Debt | Number of Fair Value of Date shares converted Debt Converted 9/21/2020 107,133,333 $ 171,413 10/5/2020 107,817,770 64,691 |
Basis of Presentation and Sum_4
Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative) - USD ($) | 1 Months Ended | 3 Months Ended | 12 Months Ended | |||
May 31, 2020 | Jun. 30, 2020 | Mar. 31, 2020 | Mar. 31, 2019 | Dec. 31, 2019 | Dec. 31, 2018 | |
Accumulated deficit | $ (65,681,240) | $ (67,864,284) | ||||
Working capital deficit | (8,866,563) | (10,931,827) | ||||
Stockholders' deficit | (8,928,291) | $ (6,296,489) | (11,701,035) | $ (5,936,593) | ||
Change in reserve for supplier advances for purchases | $ 0 | 23,948 | ||||
Inventory adjustments | $ 224,859 | |||||
Minimum [Member] | ||||||
Property and equipment estimated useful lives | 3 years | |||||
Maximum [Member] | ||||||
Property and equipment estimated useful lives | 7 years | |||||
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer One [Member] | ||||||
Concentration risk, percentage | 59.00% | 17.00% | ||||
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer Two [Member] | ||||||
Concentration risk, percentage | 61.00% | |||||
PPP [Member] | ||||||
Proceeds form loan | $ 64,895 | $ 150,000 |
Basis of Presentation and Sum_5
Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($) | 3 Months Ended | ||
Mar. 31, 2020 | Mar. 31, 2019 | ||
Accounting Policies [Abstract] | |||
Net income (loss) - basic | $ 2,183,044 | $ (400,443) | |
Change in fair value of convertible notes | (2,854,140) | ||
Interest on convertible debt | 8,735 | ||
Net loss - diluted | $ (662,361) | $ (400,443) | |
Weighted-average common shares outstanding - basic | 6,272,328,529 | 4,112,446,110 | |
Convertible debt | 6,020,875,493 | ||
Weighted-average common shares outstanding - diluted (1) | [1] | 12,293,204,022 | 4,112,446,110 |
Net income (loss) per share - basic and diluted | $ 0 | $ 0 | |
[1] | Includes potential common shares that are in excess of authorized shares. |
Basis of Presentation and Sum_6
Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Net Loss Per Share (Details) - shares | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Antidilutive securities excluded from computation of earnings per share | 46,500,000 | 8,332,756,943 |
Option and Warrants [Member] | ||
Antidilutive securities excluded from computation of earnings per share | 46,500,000 | 122,600,000 |
Convertible Notes Payable [Member] | ||
Antidilutive securities excluded from computation of earnings per share | 6,972,376,110 | |
Convertible Notes Payable Fair Value [Member] | ||
Antidilutive securities excluded from computation of earnings per share | 1,237,780,833 |
Fair Value Measurements (Detail
Fair Value Measurements (Details Narrative) | Mar. 31, 2020 |
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member] | |
Warrants outstanding, measurement input, percentage | 0.17 |
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member] | |
Warrants outstanding, measurement input, percentage | 1.59 |
Measurement Input, Price Volatility [Member] | Minimum [Member] | |
Warrants outstanding, measurement input, percentage | 320 |
Measurement Input, Price Volatility [Member] | Maximum [Member] | |
Warrants outstanding, measurement input, percentage | 348 |
Fair Value Measurements - Summa
Fair Value Measurements - Summary of Financial Instruments Measured at Fair Value (Details) - USD ($) | Mar. 31, 2020 | Dec. 31, 2019 |
Warrant liability | $ 866 | $ 1,411 |
Derivative liabilities | 1,145,655 | 834,457 |
Convertible notes at fair value | 2,562,049 | 5,814,047 |
Fair Value, Inputs, Level 1 [Member] | ||
Warrant liability | ||
Derivative liabilities | ||
Convertible notes at fair value | ||
Fair Value, Inputs, Level 2 [Member] | ||
Warrant liability | ||
Derivative liabilities | ||
Convertible notes at fair value | ||
Fair Value, Inputs, Level 3 [Member] | ||
Warrant liability | 866 | 1,411 |
Derivative liabilities | 1,145,655 | 834,457 |
Convertible notes at fair value | $ 2,562,049 | $ 5,814,047 |
Fair Value Measurements - Sum_2
Fair Value Measurements - Summary of Changes in Fair Value Measurements Using Significant Unobservable Inputs (Details) - USD ($) | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2020 | Dec. 31, 2019 | ||
Convertible Notes Payable [Member] | |||
Beginning balance | $ 5,814,047 | $ 1,156,341 | |
Purchases and issuances | 15,425 | 688,274 | |
Day one loss on value of hybrid instrument | [1] | 18,181 | 926,109 |
(Gain) loss from change in fair value | [1] | (2,871,776) | 3,423,935 |
Debt discount | 11,172 | (22,344) | |
Settlement through issuance of common stock | (83,268) | ||
Conversion to common stock | (425,000) | (275,000) | |
Ending balance | 2,562,049 | 5,814,047 | |
Warrant [Member] | |||
Beginning balance | 1,411 | 1,468 | |
Total gain included in earnings | [2] | (545) | (57) |
Ending balance | $ 866 | $ 1,411 | |
[1] | The (gains) losses related to the valuation of the convertible notes are included in "Change in fair value of convertible notes and derivatives" in the accompanying consolidated statement of operations. | ||
[2] | The gain related to the revaluation of our warrant liability is included in "Change in fair value of convertible notes and derivatives" in the accompanying consolidated statement of operations. |
Fair Value Measurements - Sum_3
Fair Value Measurements - Summary of Assumptions and the Significant Terms (Details) - Convertible Notes Payable [Member] | 3 Months Ended | 12 Months Ended |
Mar. 31, 2020USD ($)d$ / shares | Dec. 31, 2019USD ($)d$ / shares | |
Face Amount | $ | $ 1,084,629 | $ 1,244,204 |
Maximum [Member] | ||
Conversion Price | $ / shares | $ 0.00040 | $ 0.000293 |
Percentage of stock price for look-back period | 60.00% | 60.00% |
Look-back period | d | 25 | 25 |
Minimum [Member] | ||
Conversion Price | $ / shares | $ 0.00030 | $ 0.00010 |
Percentage of stock price for look-back period | 50.00% | 50.00% |
Look-back period | d | 3 | 3 |
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member] | ||
Long-term debt, measurement input | 8 | 10 |
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member] | ||
Long-term debt, measurement input | 10 | 8 |
Measurement Input, Default Interest Rate [Member] | Maximum [Member] | ||
Long-term debt, measurement input | 24 | 24 |
Measurement Input, Default Interest Rate [Member] | Minimum [Member] | ||
Long-term debt, measurement input | 20 | 20 |
Measurement Input, Discount Rate [Member] | ||
Long-term debt, measurement input |
Inventories - Schedule of Inven
Inventories - Schedule of Inventories (Details) - USD ($) | Mar. 31, 2020 | Dec. 31, 2019 |
Inventory Disclosure [Abstract] | ||
Raw Materials | $ 65,568 | $ 52,183 |
Finished Goods | 6,624 | 8,177 |
Total Inventories | 72,192 | 60,360 |
Less: Long-term inventory | (65,568) | (52,183) |
Current portion | $ 6,624 | $ 8,177 |
Property and Equipment (Details
Property and Equipment (Details Narrative) - USD ($) | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | Dec. 31, 2019 | |
Property, Plant and Equipment [Abstract] | |||
Depreciation | $ 712 | $ 1,105 | $ 1,105 |
Property and Equipment - Schedu
Property and Equipment - Schedule of Property and Equipment (Details) - USD ($) | Mar. 31, 2020 | Dec. 31, 2019 |
Property and equipment, gross | $ 216,033 | $ 216,033 |
Less: Accumulated depreciation | (209,982) | (209,270) |
Property and equipment, net | 6,051 | 6,763 |
Computer Equipment [Member] | ||
Property and equipment, gross | 25,120 | 25,120 |
Furniture and Fixtures [Member] | ||
Property and equipment, gross | 34,757 | 34,757 |
Lab Equipment [Member] | ||
Property and equipment, gross | 53,711 | 53,711 |
Telephone Equipment [Member] | ||
Property and equipment, gross | 12,421 | 12,421 |
Office Equipment - Other [Member] | ||
Property and equipment, gross | 16,856 | 16,856 |
Leasehold Improvements [Member] | ||
Property and equipment, gross | $ 73,168 | $ 73,168 |
Due to_from Officer (Details Na
Due to/from Officer (Details Narrative) - USD ($) | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | Dec. 31, 2019 | |
Due to officer | $ 199,290 | $ 122,812 | |
Repayment of officers loans | 4,200 | $ 9,950 | |
Loans from officer | 118,500 | 4,100 | |
Accrued interest expense for amount due to officer | 1,678 | 1,817 | |
Company other receivable reserves | 524,970 | 564,470 | |
Bad debt expense | 2,789 | ||
Rik Deitsch [Member] | |||
Due to officer | $ 199,290 | $ 122,812 | |
Bears interest percentage | 4.00% | 4.00% | |
Repayment of officers loans | $ 4,200 | $ 134,015 | |
Loans from officer | 118,500 | 5,000 | |
Accrued interest expense for amount due to officer | 1,678 | $ 6,330 | |
Bad debt expense | $ 39,500 | $ 0 |
Debts - Schedule of Debt (Detai
Debts - Schedule of Debt (Details) - USD ($) | Mar. 31, 2020 | Dec. 31, 2019 |
Debt Disclosure [Abstract] | ||
Note payable- Related Party (1) | $ 14,400 | $ 14,400 |
Notes payable - Unrelated third parties (Net of discount of $19,947 and $8,921, respectively) (2) | 1,394,693 | 1,385,163 |
Convertible notes payable - Unrelated third parties (Net of discount of $15,893 and $17,370, respectively) (3) | 899,407 | 872,256 |
Convertible notes payable, at fair value (Net of discount of $11,172 and $22,344, respectively) (4) | 2,562,049 | 5,814,047 |
Other advances from an unrelated third party (5) | 200,000 | 175,000 |
Ending balances | 5,070,549 | 8,260,866 |
Less: Long-term portion-Convertible Notes payable-Unrelated third parties | (225,597) | (907,912) |
Current portion | $ 4,844,952 | $ 7,352,954 |
Debts - Schedule of Debt (Det_2
Debts - Schedule of Debt (Details) (Parenthetical) | Jun. 22, 2021USD ($) | Mar. 31, 2021USD ($)$ / shares | Jul. 31, 2020USD ($) | Feb. 18, 2020USD ($)shares | Jan. 21, 2020USD ($)shares | Feb. 15, 2019USD ($) | Aug. 14, 2018USD ($)shares | Jul. 31, 2018USD ($)shares | Feb. 28, 2018USD ($) | Jul. 31, 2017USD ($) | Jun. 30, 2017USD ($) | Mar. 31, 2017USD ($) | Mar. 28, 2016USD ($) | Jun. 30, 2012USD ($) | Apr. 30, 2021USD ($) | Mar. 31, 2021USD ($)$ / shares | Feb. 28, 2021USD ($) | Oct. 31, 2020USD ($)$ / shares | Aug. 31, 2020USD ($) | Mar. 31, 2020USD ($)$ / sharesshares | Dec. 31, 2019USD ($)$ / sharesshares | Sep. 30, 2019USD ($)shares | Aug. 31, 2019USD ($) | Jun. 30, 2019USD ($)shares | Feb. 28, 2019USD ($)$ / sharesshares | Jan. 31, 2019USD ($) | Sep. 30, 2018USD ($)shares | Aug. 31, 2018USD ($)dshares | Jul. 31, 2018USD ($)dshares | Jun. 30, 2018USD ($)dshares | Jun. 30, 2018USD ($) | May 31, 2018USD ($)d | Apr. 30, 2018USD ($)d | Mar. 31, 2018USD ($)d | Feb. 28, 2018USD ($)d | Sep. 30, 2017USD ($) | May 31, 2017USD ($)d | Apr. 30, 2017USD ($)shares | Dec. 31, 2016USD ($)dshares | Feb. 29, 2020USD ($)shares | Jun. 30, 2019USD ($)shares | Jul. 31, 2017USD ($)shares | Mar. 31, 2020USD ($)d$ / sharesshares | Mar. 31, 2019USD ($) | Mar. 31, 2012USD ($)shares | May 31, 2020USD ($) | Jun. 30, 2021USD ($)$ / sharesshares | Sep. 30, 2018USD ($) | Feb. 28, 2020USD ($) | Dec. 31, 2019USD ($)d$ / sharesshares | Dec. 31, 2018USD ($)shares | Dec. 31, 2017USD ($) | Dec. 31, 2016USD ($)shares | Jul. 31, 2021$ / shares | Dec. 31, 2020USD ($)shares | Nov. 30, 2020USD ($)$ / shares | Sep. 30, 2020USD ($) | Jan. 31, 2020USD ($) | Nov. 30, 2019USD ($)$ / shares | Jul. 31, 2019USD ($) | Jun. 17, 2019USD ($)shares | May 31, 2019USD ($)shares | Oct. 31, 2018USD ($) | Jul. 12, 2018USD ($) | Apr. 28, 2018USD ($)shares | Nov. 30, 2017USD ($)shares | Oct. 31, 2017USD ($)shares | Oct. 20, 2017USD ($) | Oct. 12, 2017USD ($) | Aug. 31, 2017 | Jul. 26, 2017USD ($)$ / shares | Feb. 28, 2017$ / shares | Jan. 31, 2017USD ($) | Oct. 31, 2016USD ($) | Sep. 26, 2016USD ($) | Aug. 31, 2016USD ($)shares | Jul. 31, 2016USD ($)$ / shares | Jun. 30, 2016USD ($) | May 31, 2016USD ($) | Apr. 30, 2016USD ($) | Apr. 30, 2014$ / sharesshares | Aug. 31, 2013USD ($) | Dec. 31, 2012USD ($) | Feb. 15, 2012USD ($) | Dec. 31, 2011USD ($) | Aug. 15, 2011USD ($) | Aug. 02, 2011USD ($) | Dec. 31, 2010USD ($) | Feb. 28, 2010 | Jan. 31, 2010 |
Notes payable | $ 5,070,549 | $ 8,260,866 | $ 5,070,549 | $ 8,260,866 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | 32,676 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense, debt | 68,873 | $ 75,145 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gain loss on extinguishment of debt | (22,000) | 57,253 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument accrued interest | $ 12,150 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock, shares, issued | shares | 6,622,746,111 | 5,876,746,111 | 1,000,000 | 6,622,746,111 | 5,876,746,111 | 1,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock issued value | $ 6,622,746 | $ 5,876,746 | $ 6,622,746 | $ 5,876,746 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Amortization of debt discount | 24,873 | 38,117 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock issued price per shares | $ / shares | $ 0.18 | $ 0.18 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion, converted instrument, shares issued | shares | 250,000,000 | 250,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued for conversion of debt | $ 275,000 | $ 150,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of warrants issued | shares | 100,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant exercise price | $ / shares | $ 0.025 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value of Warrants | $ 7,370 | $ 8,147 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Month of expiration | Apr. 9, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other advances from an unrelated third party | 25,000 | $ 200,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other advances from an unrelated third party | $ 200,000 | $ 175,000 | $ 200,000 | $ 175,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Minimum [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant exercise price | $ / shares | $ 0.03 | $ 0.001 | $ 0.03 | $ 0.001 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Maximum [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant exercise price | $ / shares | $ 0.001 | $ 0.03 | $ 0.001 | $ 0.03 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other advances from an unrelated third party | $ 25,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subsequent Event [Member] | Warrant [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 7,500 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant exercise price | $ / shares | $ 0.002 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant outstanding | $ 30,417 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value of Warrants | $ 8,633 | $ 20,848 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NonRelatedPartyFiveMember | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | $ 220,506 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate, stated percentage | 0.25% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Non Related Party Ten [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 14,000 | $ 14,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | 70,000 | 70,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Settlement Agreement [Member] | Non Related Party Ten [Member] | Subsequent Event [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cash settlement | $ 84,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debtentures [Member] | Unrelated Third Party [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate, stated percentage | 12.00% | 12.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | $ 2,820 | $ 63,001 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock, shares, issued | shares | 105,157,409 | 105,157,409 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock issued value | $ 147,220 | $ 147,220 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable | $ 110,000 | $ 32,400 | $ 110,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt maturity date | Sep. 8, 2017 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion, converted instrument, shares issued | shares | 179,800,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion principle amount | 46,999 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument conversion feature | $ 298,575 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion percentage | 60.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trading days | d | 25 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Debtentures [Member] | Non Related Party Fourteen [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 0 | $ 3,800 | $ 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | $ 65,600 | 65,600 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | 10,476 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, unamortized discount net issuance costs | $ 4,035 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Amortization of debt discount | 950 | 2,850 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable | $ 65,600 | 76,076 | $ 76,076 | $ 65,600 | 76,076 | $ 56,567 | $ 56,567 | $ 50,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument convertible debt percentage | 2.50% | 2.50% | 2.50% | 2.50% | 2.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock issued price per shares | $ / shares | $ 0.05 | $ 0.05 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion, converted instrument, shares issued | shares | 1,000,000 | 5,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Back and End Note [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate, stated percentage | 8.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt principal amount | 71,500 | 71,500 | $ 100,000 | 71,500 | 71,500 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable | 192,139 | 458,957 | $ 65,000 | 192,139 | 458,957 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument convertible debt percentage | 24.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion percentage | 60.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trading days | d | 25 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative loss | $ 110,700 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Back and End Note [Member] | Unrelated Third Party [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate, stated percentage | 8.00% | 8.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt principal amount | 66,000 | 66,000 | 66,000 | 66,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable | 174,929 | 417,577 | $ 60,000 | $ 60,000 | 174,929 | 417,577 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument convertible debt percentage | 24.00% | 24.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion percentage | 60.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trading days | d | 25 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative loss | $ 68,067 | $ 68,067 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Restatement of Promissory Notes [Member] | Subsequent Event [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate, stated percentage | 2.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt principal amount | $ 166,926 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument accrued interest | $ 23,258 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Payable Unrelated Party [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 19,947 | 8,921 | 19,947 | 8,921 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Non Related Parties Convertible Notes Payable [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 15,893 | 17,370 | 15,893 | 17,370 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 11,172 | 22,344 | 5,000 | $ 11,172 | 22,344 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, unamortized discount net issuance costs | 5,000 | 5,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Outstanding notes payable | 589,829 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Amortization of debt discount | $ 8,200 | $ 28,421 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable | 553,301 | $ 70,000 | $ 70,000 | $ 70,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument convertible debt percentage | 0.05% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of warrants issued | shares | 110,000,000 | 110,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant exercise price | $ / shares | $ 0.001 | $ 0.001 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant outstanding | $ 8,147 | $ 8,147 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable [Member] | Warrant [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of warrants issued | shares | 44,000,000 | 110,000,000 | 44,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant exercise price | $ / shares | $ 0.001 | $ 0.001 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value of Warrants | $ 7,370 | $ 8,147 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Month of expiration | Aug. 31, 2020 | Aug. 31, 2019 | Aug. 31, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable [Member] | Common Stock [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, unamortized discount net issuance costs | $ 6,400 | $ 6,400 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock, shares, issued | shares | 6,000,001 | 6,000,001 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock issued value | $ 1,800 | $ 1,800 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable [Member] | Minimum [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument convertible price per share | $ / shares | $ 0.00030 | $ 0.00010 | $ 0.00030 | $ 0.00010 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion percentage | 50.00% | 50.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trading days | d | 3 | 3 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable [Member] | Maximum [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument convertible price per share | $ / shares | $ 0.00040 | $ 0.000293 | $ 0.00040 | $ 0.000293 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion percentage | 60.00% | 60.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trading days | d | 25 | 25 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable [Member] | Subsequent Event [Member] | Warrant [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 29,481 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant exercise price | $ / shares | $ 0.001 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable [Member] | Subsequent Event [Member] | Minimum [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument convertible price per share | $ / shares | $ 0.0003 | $ 0.0003 | $ 0.0008 | $ 0.0008 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable [Member] | Unrelated Third Party [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate, stated percentage | 8.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | $ 63,144 | $ 3,232 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt principal amount | $ 12,629 | 12,629 | $ 12,629 | $ 12,629 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Non-payment penalty charges | $ 12,442 | $ 12,442 | $ 6,400 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable | 38,404 | 62,253 | 34,060 | 34,060 | $ 64,000 | 38,404 | 62,253 | 856 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt maturity date | May 4, 2018 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest payable | 10,143 | $ 9,782 | 10,143 | 9,782 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument convertible debt percentage | 20.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Deposit liabilities, accrued interest | $ 8,607 | 8,607 | 21,399 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion, converted instrument, shares issued | shares | 800,000,000 | 50,670,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion principle amount | $ 16,752 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument conversion feature | $ 70,938 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion percentage | 60.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trading days | d | 20 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable [Member] | Non Related Party Fourteen [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | 12,149 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Non-payment penalty charges | $ 148,225 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable | $ 60,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable [Member] | Non Related Party Fifteen [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, unamortized discount net issuance costs | $ 10,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt default, amount | $ 3,300 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock, shares, issued | shares | 5,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable | $ 60,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable [Member] | Non Related Party Twenty [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 255,655 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, unamortized discount net issuance costs | $ 62,950 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock, shares, issued | shares | 10,250,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock issued value | $ 6,542 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Amortization of debt discount | 62,950 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable | 618,250 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument conversion feature | $ 249,113 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable [Member] | Non Related Party Twenty [Member] | Minimum [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument convertible debt percentage | 0.03% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable [Member] | Non Related Party Twenty [Member] | Maximum [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument convertible debt percentage | 0.10% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable [Member] | Unrelated Third Parties [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 9,250 | 9,250 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | 101,750 | 101,750 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, unamortized discount net issuance costs | 14,500 | 14,500 | $ 14,500 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt settlement | 915,300 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Outstanding notes payable | 839,407 | 839,407 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Amortization of debt discount | 1,542 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable | $ 159,500 | $ 159,500 | $ 159,500 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock issued price per shares | $ / shares | $ 0.0002 | $ 0.0002 | $ 0.000275 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Amortization | $ 55,222 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable [Member] | Unrelated Third Parties [Member] | Minimum [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | $ 33,000 | $ 33,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock issued price per shares | $ / shares | $ 0.002 | $ 0.002 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable [Member] | Unrelated Third Parties [Member] | Maximum [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | $ 68,750 | $ 68,750 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock issued price per shares | $ / shares | $ 0.0005 | $ 0.0005 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable [Member] | Unrelated Third Parties [Member] | Subsequent Event [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 1,900 | $ 1,650 | 7,550 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt principal amount | 20,900 | $ 16,500 | $ 38,500 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayments of convertible debt | $ 19,500 | $ 19,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable [Member] | 16 Unrelated Third Parties [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 17,370 | 17,370 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable | 736,180 | 736,180 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Amortization | $ 9,185 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable [Member] | Brewer and Associates Consulting, LLC [Member] | Non Related Party Twenty [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayments of notes payable | $ 60,000 | $ 40,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt principal amount | $ 20,000 | 20,000 | 20,000 | 20,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable | $ 120,000 | $ 50,687 | $ 56,373 | 50,687 | $ 56,373 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Extinguishment debt extinguishment assets payments | 7,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative, collateral, obligation to return cash | $ 36,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable [Member] | Note Agreement [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt principal amount | $ 1,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from loan | $ 112,799 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable [Member] | Note Agreement [Member] | Subsequent Event [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock issued during period, restricted stock | shares | 240,350,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock issued during period, restricted stock value | $ 120,175 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument fair value | $ 2,344,399 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceeds from loan | $ 128,937 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable [Member] | Promissory Note [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt principal amount | $ 75,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable | 60,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest payable | 15,900 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative loss | 75,900 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable [Member] | Promissory Note [Member] | Settlement Agreement [Member] | Non Related Party Fifteen [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock, shares, issued | shares | 1,000,000 | 1,000,000 | 1,000,000 | 1,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock issued value | $ 1,500 | $ 1,500 | $ 1,500 | $ 1,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable | 60,000 | 60,000 | 60,000 | 60,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable [Member] | Convertible Promissory Note [Member] | Non Related Party Twenty Five [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 33,516 | 33,516 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable | 540,000 | 540,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable [Member] | Convertible Debtentures [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate, stated percentage | 8.00% | 8.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt principal amount | 38,301 | 38,301 | 38,301 | 38,301 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable | 103,311 | 246,819 | $ 49,819 | 103,311 | 246,819 | $ 49,819 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt maturity date | Feb. 13, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument convertible debt percentage | 24.00% | 24.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion percentage | 60.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trading days | d | 25 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable [Member] | Convertible Debenture [Member] | Restricted Stock [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt principal amount | $ 15,000 | 15,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion, converted instrument, shares issued | shares | 52,244,433 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued for conversion of debt | $ 37,011 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable [Member] | Restatement of Promissory Notes [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayments of convertible debt | $ 75,900 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion percentage | 50.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Payable One [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest expense, debt | 4,721 | 4,196 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Payable One [Member] | Promissory Note [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | 14,400 | 14,400 | 14,400 | 14,400 | $ 12,000 | 12,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, unamortized discount net issuance costs | 2,400 | 2,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Payable One [Member] | Director [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | $ 200,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate, stated percentage | 12.00% | 10.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | 164,276 | 159,555 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Payable Two [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | 1,394,693 | 1,385,163 | 1,394,693 | 1,385,163 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, unamortized discount net issuance costs | 19,947 | 8,921 | 19,947 | 8,921 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Payable Two [Member] | UniversityCentreWestLtdMember | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument rent expenses | $ 55,410 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Payable Two [Member] | Related Party [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | $ 50,000 | $ 75,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate, stated percentage | 2.00% | 2.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | 53,001 | 49,967 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayments of notes payable | $ 25,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt principal amount | 50,000 | 50,000 | 50,000 | 50,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock, shares, issued | shares | 5,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Payable Two [Member] | Related Party One [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | 46,200 | 43,166 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt principal amount | 50,000 | 50,000 | 50,000 | 50,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Payable Two [Member] | Unrelated Third Party [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | $ 180,250 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate, stated percentage | 2.50% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Payable Two [Member] | NonRelatedPartyFiveMember | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | $ 200,000 | $ 12,500 | 200,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate, stated percentage | 10.00% | 15.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | 3,528 | 3,212 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs, gross | 5,500 | 5,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Payable Two [Member] | Non Related Party Two [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 2,947 | 4,421 | 2,947 | 4,421 | $ 3,945 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | 282,983 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, unamortized discount net issuance costs | 3,616 | 3,616 | $ 329 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock, shares, issued | shares | 10,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Amortization of debt discount | 1,474 | 1,474 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Payable Two [Member] | Non Related Party Two [Member] | Subsequent Event [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 5,895 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | $ 333,543 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock, shares, issued | shares | 333,543 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Payable Two [Member] | Non Related Party Nine [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 0 | 12,149 | $ 10,000 | $ 12,381 | $ 12,381 | 0 | 4,127 | 12,149 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | 61,746 | 60,000 | 61,746 | 60,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, unamortized discount net issuance costs | 8,254 | 10,000 | 8,254 | $ 10,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Non-payment penalty charges | 148,225 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock, shares, issued | shares | 10,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock issued value | $ 4,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Long-term debt, maturities | $ 76,076 | $ 76,076 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest payable | 7,710 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument convertible debt percentage | 2.00% | 2.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Payable Two [Member] | Non Related Party Ten [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 20,000 | $ 0 | 20,000 | $ 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | 50,000 | 120,000 | 50,000 | 120,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, unamortized discount net issuance costs | 120,000 | 120,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock, shares, issued | shares | 1,500,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock issued value | $ 2,250 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Payable Two [Member] | Non Related Party Eleven [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 20,000 | 20,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | 50,000 | 50,000 | 18,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, unamortized discount net issuance costs | 120,000 | 120,000 | $ 3,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cash settlement | $ 37,500 | $ 37,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock, shares, issued | shares | 125,000,000 | 125,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock issued value | $ 87,500 | $ 87,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Payable Two [Member] | Liquid Packaging Resources Inc [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Non-payment penalty charges | $ 100,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Payable Two [Member] | Southridge Partners, LLP [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | $ 281,772 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Noncash transaction, value consideration received | $ 281,772 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Payable Two [Member] | Settlement Agreement [Member] | NonRelatedPartyFiveMember | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | 191,329 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Payable Two [Member] | Settlement Agreement [Member] | Non Related Party Two [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | 333,543 | 333,543 | 333,543 | 333,543 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | 45,362 | 25,127 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Payable Two [Member] | Settlement Agreement [Member] | Non Related Party Four [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | 42,500 | 39,466 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Payable Two [Member] | Settlement Agreement [Member] | Non Related Party Six [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | 80,034 | 92,728 | 80,034 | 92,728 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayments of notes payable | 12,694 | 42,698 | $ 34,976 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cash settlement | $ 20,927 | 20,927 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Payable Two [Member] | Settlement Agreement [Member] | Non Related Party Six [Member] | Subsequent Event [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayments of notes payable | 5,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayments of lines of credit | $ 2,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Outstanding notes payable | 33,874 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cash settlement | $ 130,401 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Payable Two [Member] | Settlement Agreement [Member] | Non Related Party Nine [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock, shares, issued | shares | 10,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock issued value | $ 3,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Payable Two [Member] | Settlement Agreement [Member] | Non Related Party Eleven [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | 2,000 | 2,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayments of notes payable | 18,000 | 18,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock, shares, issued | shares | 7,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock issued value | $ 5,600 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Payable Two [Member] | Settlement Agreement [Member] | Liquid Packaging Resources Inc [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | $ 50,000 | $ 50,000 | $ 350,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayments of lines of credit | $ 25,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt principal amount | $ 175,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Non-payment penalty charges | $ 25,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sale of stock, number of shares | shares | 142,858 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Payable Two [Member] | Promissory Note [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | $ 10,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate, stated percentage | 10.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument accrued interest | 4,006 | 3,755 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Payable Two [Member] | Promissory Note [Member] | Unrelated Third Party [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | $ 150,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate, stated percentage | 2.50% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Payable Two [Member] | Promissory Note [Member] | NonRelatedPartyOneMember | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 2,765 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | $ 282,983 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate, stated percentage | 2.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayments of notes payable | $ 220,506 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock, shares, issued | shares | 5,000,000 | 5,000,000 | 2,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock issued value | $ 5,500 | $ 5,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Amortization of debt discount | 2,765 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Payable Two [Member] | Promissory Note [Member] | Non Related Party Three [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | 15,000 | 15,000 | $ 60,000 | 15,000 | 15,000 | $ 75,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate, stated percentage | 10.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | 1,371 | 1,371 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument accrued interest | 15,900 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Long-term debt, maturities | $ 15,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Payable Two [Member] | Promissory Note [Member] | Non Related Party Four [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | $ 50,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate, stated percentage | 2.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Payable Two [Member] | Promissory Note [Member] | Non Related Party Seven [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | 50,000 | 50,000 | 50,000 | $ 50,000 | 50,000 | 50,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Amortization of debt discount | $ 10,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Payable Two [Member] | Promissory Note [Member] | Non Related Party Eight [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | 29,500 | 30,000 | $ 36,000 | 29,500 | 30,000 | 33,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | 3,000 | 4,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, unamortized discount net issuance costs | 6,000 | 6,000 | 6,000 | $ 6,000 | $ 3,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayments of notes payable | $ 5,000 | $ 7,000 | $ 1,500 | 2,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Amortization of debt discount | 7,500 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Payable Two [Member] | Promissory Note [Member] | Non Related Party Eight [Member] | Subsequent Event [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | $ 30,000 | $ 30,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate, stated percentage | 12.00% | 12.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument convertible price per share | $ / shares | $ 0.01 | $ 0.01 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayments of notes payable | $ 1,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Payable Two [Member] | Promissory Note [Member] | Non Related Party Nine [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 3,200 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | $ 60,000 | 50,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, unamortized discount net issuance costs | $ 10,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock, shares, issued | shares | 1,000,000 | 5,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock issued value | $ 1,700 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Payable Two [Member] | Promissory Note [Member] | Non Related Party Ten [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 14,000 | 14,000 | 5,600 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | $ 70,000 | $ 70,000 | 120,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, unamortized discount net issuance costs | $ 20,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock, shares, issued | shares | 46,000,000 | 46,000,000 | 10,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock issued value | $ 32,200 | $ 32,200 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Payable Two [Member] | Promissory Note [Member] | Non Related Party Eleven [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock, shares, issued | shares | 5,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock issued value | $ 2,900 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Payable Two [Member] | Promissory Note Two [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | $ 101,818 | 90,500 | 90,500 | $ 201,818 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate, stated percentage | 12.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | 32,676 | 52,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument convertible price per share | $ / shares | $ 0.008 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayments of notes payable | $ 6,365 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayments of lines of credit | 22,500 | 13,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt settlement | 88,500 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gain loss on extinguishment of debt | 15,500 | 18,841 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Outstanding notes payable | 91,156 | 91,156 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Payable Two [Member] | Promissory Note Two [Member] | Scheduled Payments Through May 1, 2020 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | 21,023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayments of lines of credit | $ 104,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Payable Two [Member] | Promissory Note Two [Member] | Settlement [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | 32,676 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Payable Two [Member] | Reverse Stock Split [Member] | Settlement Agreement [Member] | Liquid Packaging Resources Inc [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Non-payment penalty charges | $ 350,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sale of stock, number of shares | shares | 5,714,326 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cash settlement | $ 450,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt default, amount | $ 100,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Payable Two [Member] | Note Holder [Member] | Non Related Party Nine [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 8,678 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, unamortized discount net issuance costs | 18,678 | $ 10,000 | $ 10,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt default, amount | $ 2,381 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock, shares, issued | shares | 5,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common stock issued value | $ 60,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Payable Two [Member] | Director [Member] | Promissory Note Two [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | 143,656 | 160,633 | 143,656 | 160,633 | 192,974 | $ 200,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate, stated percentage | 12.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accrued interest | 50,971 | $ 40,033 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayments of notes payable | $ 8,844 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Payable Two [Member] | Former Director [Member] | Promissory Note Two [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes payable | $ 100,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note Payable Two [Member] | Two Unrelated Parties [Member] | Settlement Agreement [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayments of notes payable | 130,401 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayments of lines of credit | $ 40,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable Three of the Notes [Member] | Unrelated Third Parties [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayments of convertible debt | 13,500 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable Six of the Notes [Member] | Unrelated Third Parties [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayments of convertible debt | $ 87,100 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion, converted instrument, shares issued | shares | 800,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Loans One [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, unamortized discount net issuance costs | 11,172 | $ 22,344 | 11,172 | 22,344 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable | 2,562,049 | 5,814,047 | 2,562,049 | 5,814,047 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable One [Member] | Convertible Debtentures [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate, stated percentage | 8.00% | 8.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt principal amount | 220,000 | 220,000 | 220,000 | 220,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable | $ 200,000 | 591,197 | 1,412,175 | $ 200,000 | 591,197 | 1,412,175 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt maturity date | Feb. 28, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument convertible debt percentage | 24.00% | 24.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion percentage | 60.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trading days | d | 25 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative loss | $ 1,646,242 | $ 1,646,242 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable One [Member] | Convertible Debtentures [Member] | Unrelated Third Party [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate, stated percentage | 8.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt principal amount | 66,000 | 66,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable | 417,576 | $ 60,000 | 417,576 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument convertible debt percentage | 24.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion percentage | 60.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trading days | d | 25 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative loss | $ 48,418 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable One [Member] | Convertible Debtentures [Member] | Unrelated Third Party [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt principal amount | 66,000 | 66,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable | 174,930 | 174,930 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable One [Member] | Back and End Note [Member] | Unrelated Third Party [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable | $ 60,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable Two [Member] | Convertible Debtentures [Member] | Unrelated Third Party [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate, stated percentage | 8.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt principal amount | 60,000 | 60,000 | 60,000 | 60,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable | 154,929 | 369,372 | $ 60,000 | 154,929 | 369,372 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt maturity date | May 31, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument convertible debt percentage | 24.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion percentage | 60.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trading days | d | 25 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative loss | $ 59,257 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable Three [Member] | Convertible Debtentures [Member] | Unrelated Third Party [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate, stated percentage | 8.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt principal amount | 31,500 | 31,500 | 31,500 | 31,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable | 77,195 | 183,565 | $ 31,500 | 77,195 | 183,565 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt maturity date | Aug. 31, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument convertible debt percentage | 24.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion percentage | 60.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trading days | d | 25 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative loss | $ 23,794 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable Four [Member] | Convertible Debtentures [Member] | Unrelated Third Party [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate, stated percentage | 8.00% | 8.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable | $ 50,000 | 113,546 | 180,176 | $ 50,000 | 113,546 | 180,176 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt maturity date | Jul. 31, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument convertible debt percentage | 24.00% | 24.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion percentage | 55.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trading days | d | 15 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative loss | $ 46,734 | $ 46,734 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable Five [Member] | Convertible Debtentures [Member] | Non Related Party Twenty Two[Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest rate, stated percentage | 8.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable | 44,557 | 70,635 | $ 20,000 | 44,557 | 70,635 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt maturity date | Aug. 31, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument convertible debt percentage | 24.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Conversion percentage | 55.00% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trading days | d | 15 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative loss | $ 17,829 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable | 151,800 | 253,000 | 151,800 | 253,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable [Member] | Four Tranches [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable | 387,799 | 387,799 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Note [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 22,344 | 22,344 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument, unamortized discount net issuance costs | 40,000 | 40,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repayments of notes payable | 27,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt principal amount | 112,799 | 112,799 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Amortization of debt discount | 4,688 | 11,172 | $ 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable | 225,597 | 240,000 | $ 240,000 | 225,597 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interest payable | 11,412 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion, converted instrument, shares issued | shares | 500,000,000 | 750,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt conversion principle amount | $ 175,000 | $ 100,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued for conversion of debt | $ 425,000 | 275,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative loss | $ 240,000 | $ 610,210 | $ 240,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument conversion terms | The Noteholder has the right to convert the note into shares of Common Stock at a conversion price of the lower of $0.0005 or 50% discount to the average trading price of the three lowest closing stock prices for the twenty days prior to the notice of conversion. | The Noteholder has the right to convert the note into shares of Common Stock at a conversion price of the lower of $0.0005 or 50% discount to the average trading price of the three lowest closing stock prices for the twenty days prior to the notice of conversion. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stock issued during period, restricted stock | shares | 16,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Note [Member] | Maximum [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt instrument convertible price per share | $ / shares | $ 0.0005 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt principal amount | $ 1,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Note [Member] | Unrelated Third Party [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 11,172 | 22,344 | 11,172 | 22,344 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable | 480,000 | $ 800,000 | 480,000 | $ 800,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Note [Member] | Note Agreement [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable | $ 121,560 | $ 121,560 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt maturity date | Mar. 31, 2023 |
Stockholders' Deficit (Details
Stockholders' Deficit (Details Narrative) - USD ($) | Feb. 18, 2020 | Jan. 21, 2020 | Jun. 30, 2018 | Oct. 30, 2017 | Mar. 31, 2020 | Feb. 29, 2020 | Jan. 31, 2020 | Jun. 30, 2019 | Apr. 30, 2019 | Mar. 31, 2020 | Mar. 31, 2019 | Dec. 31, 2019 | Sep. 30, 2018 | Mar. 07, 2018 | Mar. 06, 2018 | Nov. 30, 2017 | Apr. 30, 2016 |
Common stock, shares authorized | 8,000,000,000 | 8,000,000,000 | 8,000,000,000 | 8,000,000,000 | 2,000,000,000 | ||||||||||||
Preferred stock, shares authorized | 20,000,000 | 20,000,000 | 20,000,000 | 20,000,000 | |||||||||||||
Available for distribution, cash per share | $ 0.133 | ||||||||||||||||
Number of shares issued for conversion of debt, shares | 250,000,000 | 250,000,000 | |||||||||||||||
Notes payable | $ 5,070,549 | $ 5,070,549 | $ 8,260,866 | ||||||||||||||
Common stock per share value | $ 0.001 | $ 0.001 | $ 0.001 | ||||||||||||||
Restricted Stock [Member] | |||||||||||||||||
Equity compensation charge | $ 7,500 | $ 21,500 | |||||||||||||||
Share-based payment arrangement, nonvested award, cost not yet recognized, amount | $ 1,000 | 1,000 | |||||||||||||||
Restricted Stock [Member] | Consultant [Member] | |||||||||||||||||
Stock issued during the period for services, shares | 15,000,000 | 120,000,000 | |||||||||||||||
Stock issued during the period for services | $ 6,000 | $ 24,000 | |||||||||||||||
Consultant Agreement [Member] | Restricted Stock [Member] | |||||||||||||||||
Stock issued during the period for services, shares | 100,000,000 | ||||||||||||||||
Common stock per share value | $ 0.0012 | ||||||||||||||||
Non Related Party Ten [Member] | |||||||||||||||||
Notes payable | 70,000 | 70,000 | |||||||||||||||
Debt discount | 14,000 | 14,000 | |||||||||||||||
Three note holder [Member] | Restricted Stock [Member] | |||||||||||||||||
Equity compensation charge | $ 120,000 | 0 | $ 30,000 | ||||||||||||||
Note Payable Two [Member] | |||||||||||||||||
Notes payable | 1,394,693 | 1,394,693 | 1,385,163 | ||||||||||||||
Debt instrument, unamortized discount net issuance costs | 19,947 | 19,947 | 8,921 | ||||||||||||||
Note Payable Two [Member] | Non Related Party Ten [Member] | |||||||||||||||||
Notes payable | 50,000 | 50,000 | 120,000 | ||||||||||||||
Debt instrument, unamortized discount net issuance costs | 120,000 | 120,000 | |||||||||||||||
Debt discount | $ 20,000 | 20,000 | $ 0 | ||||||||||||||
Number of shares issued for settlement of debt | 125,000,000 | ||||||||||||||||
Shares issued for settlement of debt amount | $ 87,500 | ||||||||||||||||
Other expense, debt | $ 37,500 | ||||||||||||||||
Notes Payable [Member] | |||||||||||||||||
Number of shares issued for conversion of debt, shares | 500,000,000 | 500,000,000 | |||||||||||||||
Debt instrument, face amount | $ 175,000 | $ 175,000 | |||||||||||||||
Notes Payable [Member] | Maximum [Member] | |||||||||||||||||
Debt instrument, face amount | $ 1,000,000 | $ 1,000,000 | |||||||||||||||
Promissory Note [Member] | Debt Modification and Penalty [Member] | |||||||||||||||||
Stock issuance during period, shares | 121,000,000 | 121,000,000 | |||||||||||||||
Stock issuance during period, value | $ 77,200 | $ 77,200 | |||||||||||||||
Promissory Note [Member] | Note Payable Two [Member] | |||||||||||||||||
Notes payable | $ 10,000 | ||||||||||||||||
Promissory Note [Member] | Note Payable Two [Member] | Non Related Party Ten [Member] | |||||||||||||||||
Notes payable | 70,000 | 70,000 | $ 120,000 | ||||||||||||||
Debt instrument, unamortized discount net issuance costs | 20,000 | ||||||||||||||||
Debt discount | $ 14,000 | $ 14,000 | $ 5,600 | ||||||||||||||
Series A Preferred Stock [Member] | |||||||||||||||||
Stock issuance during period, shares | 3,000,000 |
Stockholders' Deficit - Schedul
Stockholders' Deficit - Schedule of Common Stock Issued for Conversion of Debt (Details) - USD ($) | Feb. 18, 2020 | Jan. 21, 2020 |
Equity [Abstract] | ||
Number of shares converted | 250,000,000 | 250,000,000 |
Fair value of debt converted | $ 275,000 | $ 150,000 |
Stock Warrants (Details Narrati
Stock Warrants (Details Narrative) - USD ($) | 1 Months Ended | 3 Months Ended | 12 Months Ended | ||||||
Dec. 31, 2019 | Feb. 28, 2019 | Mar. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | Mar. 31, 2017 | Apr. 04, 2016 | Mar. 03, 2016 | Apr. 30, 2014 | |
Notes Payable | $ 8,260,866 | $ 5,070,549 | $ 8,260,866 | ||||||
Number of warrants to purchase common stock | 100,000 | ||||||||
Warrants, exercise price per share | $ 0.025 | ||||||||
Fair value of warrants | 7,370 | $ 8,147 | |||||||
Warrants, expiration date | Apr. 9, 2019 | ||||||||
Three Convertible Notes Payable [Member] | |||||||||
Notes Payable | 22,000 | $ 70,000 | 22,000 | ||||||
Warrants, exercise price per share | $ 0.001 | ||||||||
Three Year Warrant [Member] | |||||||||
Notes Payable | $ 80,000 | ||||||||
Warrants, term | 3 years | 3 years | |||||||
Number of warrants to purchase common stock | 600,000 | 4,000,000 | |||||||
Warrants, exercise price per share | $ 0.005 | $ 0.05 | |||||||
Fair value of warrants | 0 | 539 | |||||||
Warrants, expiration date | Mar. 30, 2020 | Apr. 4, 2019 | |||||||
Three Year Warrant [Member] | Convertible Notes Payable [Member] | |||||||||
Fair value of warrants | $ 0 | ||||||||
Five Year Warrant [Member] | |||||||||
Warrants, term | 5 years | ||||||||
Number of warrants to purchase common stock | 2,500,000 | ||||||||
Warrants, exercise price per share | $ 0.03 | ||||||||
Fair value of warrants | $ 866 | 872 | |||||||
Warrants, expiration date | Mar. 3, 2021 | ||||||||
Warrant [Member] | |||||||||
Warrants, intrinsic value | $ 0 | $ 0 | |||||||
Stock price | $ 0.0006 | $ 0.0006 |
Stock Warrants - Schedule of Wa
Stock Warrants - Schedule of Warrants Issued (Details) - USD ($) | 1 Months Ended | |
Dec. 31, 2019 | Feb. 28, 2019 | |
Share-based Payment Arrangement [Abstract] | ||
Number of Warrants | 44,000,000 | 110,000,000 |
Fair Value of Warrants | $ 7,370 | $ 8,147 |
Month of Expiration | August, 2020 | August, 2019 |
Stock Warrants - Summary of War
Stock Warrants - Summary of Warrants Outstanding (Details) - $ / shares | 3 Months Ended | 12 Months Ended |
Mar. 31, 2020 | Dec. 31, 2019 | |
Weighted Average Exercise Price, Warrants, Beginning | $ 0.0028 | |
Weighted Average Exercise Price, Warrants, Ending | $ 0.0026 | $ 0.0028 |
Warrant [Member] | ||
Number of warrants outstanding, Beginning | 52,500,000 | 12,600,000 |
Number of warrants, Exercised | ||
Number of warrants, Issued | 154,000,000 | |
Number of warrants, Expired | (6,000,000) | (114,100,000) |
Number of warrants outstanding, Ending | 46,500,000 | 52,500,000 |
Weighted Average Exercise Price, Warrants, Beginning | $ 0.0028 | $ 0.026 |
Weighted Average Exercise Price, Warrants, Exercised | ||
Weighted Average Exercise Price, Warrants, Issued | 0.001 | |
Weighted Average Exercise Price, Warrants, Expired | 0.005 | 0.0027 |
Weighted Average Exercise Price, Warrants, Ending | $ 0.0026 | $ 0.0028 |
Stock Warrants - Summary of Fix
Stock Warrants - Summary of Fixed Price Warrants Outstanding (Details) - $ / shares | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2020 | Dec. 31, 2019 | Apr. 30, 2014 | |
Exercise Price | $ 0.025 | ||
Weighted Average Exercise Price | $ 0.0026 | $ 0.0028 | |
Maximum [Member] | |||
Exercise Price | 0.001 | 0.03 | |
Minimum [Member] | |||
Exercise Price | $ 0.03 | $ 0.001 | |
Weighted Average Number Outstanding | 46,500,000 | 10,187,671 | |
Weighted Average Contractual Life | 5 months 1 day | 7 months 13 days |
Accrued Expenses - Schedule of
Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($) | Mar. 31, 2020 | Dec. 31, 2019 |
Payables and Accruals [Abstract] | ||
Accrued consulting fees | $ 161,550 | $ 161,550 |
Accrued settlement expenses | 35,000 | 35,000 |
Accrued payroll taxes | 179,911 | 167,906 |
Accrued interest | 238,354 | 231,186 |
Accrued others | 15,459 | 16,905 |
Total | $ 630,274 | $ 612,547 |
Prepaid Expenses (Details Narra
Prepaid Expenses (Details Narrative) - USD ($) | Mar. 31, 2020 | Dec. 31, 2019 |
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] | ||
Future reserve for purchases | $ 0 | $ 23,948 |
Total valuation allowance for prepaid | $ 224,859 | $ 224,859 |
Prepaid Expenses - Schedule of
Prepaid Expenses - Schedule of Prepaid Expenses (Details) - USD ($) | Mar. 31, 2020 | Dec. 31, 2019 |
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] | ||
Supplier advances for future purchases | $ 224,859 | $ 224,859 |
Reserve for supplier advances | (224,859) | (224,859) |
Net supplier advances | ||
Prepaid professional fees | 20,265 | 8,650 |
Deferred stock compensation | 1,000 | 8,500 |
Total | $ 21,265 | $ 17,150 |
Commitments and Contingencies_2
Commitments and Contingencies (Details Narrative) - USD ($) | Feb. 15, 2019 | Aug. 01, 2017 | Apr. 12, 2017 | Aug. 31, 2016 | Feb. 28, 2016 | Oct. 30, 2015 | Jul. 31, 2015 | Mar. 31, 2020 | Mar. 31, 2019 | Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2016 |
Operating lease term | 3 years | |||||||||||
Operating lease due | $ 3,200 | |||||||||||
Lease expiration date | Feb. 28, 2019 | |||||||||||
Common stock shares issued | 6,622,746,111 | 5,876,746,111 | 1,000,000 | |||||||||
Note issued | $ 87,500 | $ 32,400 | ||||||||||
Shares issued, price per share | $ 0.18 | |||||||||||
Accrued liabilities for commissions, expense and taxes | 142,500 | $ 142,500 | ||||||||||
Equity compensation charges | $ 31,750 | |||||||||||
Accrued expenses | $ 19,150 | $ 19,150 | ||||||||||
Share based compensation, shares not yet issued | 1,500,000 | |||||||||||
Accrued interest | $ 32,676 | |||||||||||
Loss contingency, allegations | The violations alleged against the Company by the SEC include: (a) raising over $920,000 in at least two private placement offerings for which the Company failed to file required registration statements with the SEC; (b) issuing a series of materially false or misleading press releases; (c) making false statements in at least one Form 10-Q; and (d) failing to make required public filings with the SEC to disclose the Company's issuance of millions of shares of stock. The lawsuit makes additional allegations against Mr. McManus and Mr. Deitsch, including that Mr. McManus acted as a broker without SEC registration and defrauded at least one investor by making false statements about the Company, that Mr. Deitsch engaged in manipulative trades of the Company's stock by offering to pay more for shares he was purchasing than the amount the seller was willing to take, and that Mr. Deitsch failed to make required public filings with the SEC. The lawsuit seeks both injunctive and monetary relief. | |||||||||||
Consulting Services Agreement [Member] | Restricted Stock [Member] | ||||||||||||
Consulting service term | 5 years | |||||||||||
Common stock shares issued | 500,000 | |||||||||||
Debt instrument, interest rate | 8.00% | |||||||||||
Note issued | $ 50,000 | |||||||||||
Consultant Agreement [Member] | ||||||||||||
Share-based compensation arrangement by share-based payment award, non-option equity instruments, granted | 2,500,000 | |||||||||||
Consultant Agreement [Member] | Common Stock [Member] | ||||||||||||
Debt instrument periodic payment | $ 3,000 | |||||||||||
Recepto Pharm Leases [Member] | ||||||||||||
Operating lease due | $ 6,900 | |||||||||||
Lease, description | ReceptoPharm leases a lab and renewed its operating lease agreement for five years beginning August 1, 2017 for monthly payments of approximately $6,900 with a 5% increase each year. | |||||||||||
Paul Reid et al [Member] | ||||||||||||
Loss contingency, damages sought, value | $ 315,000 | |||||||||||
Get Credit Healthy, Inc. and Rik Deitsch,[Member] | ||||||||||||
Loss contingency, damages sought, value | $ 100,000 | |||||||||||
Long-term debt | $ 101,818 | |||||||||||
Long-term debt, accured interest | $ 21,023 | |||||||||||
Payments for legal settlements | $ 104,000 |
Commitments and Contingencies -
Commitments and Contingencies - Schedule of Lease Cost and Balance Sheet Information (Details) - USD ($) | 3 Months Ended | |
Mar. 31, 2020 | Dec. 31, 2019 | |
Commitments and Contingencies Disclosure [Abstract] | ||
Operating lease cost | $ 22,255 | |
Short-term lease cost | 11,219 | |
Total lease cost | 33,474 | |
Operating ROU Assets | 200,276 | $ 207,530 |
Operating lease obligations, current portion | 75,588 | 73,278 |
Operating lease obligations, non-current portion | 123,576 | $ 143,322 |
Total operating lease obligations | $ 199,164 | |
Weighted average remaining lease term (in years) - operating leases | 2 years 5 months 1 day | |
Weighted average discount rate-operating leases | 8.00% | |
Cash paid for amounts included in the measurement of operating lease liabilities | $ 32,437 |
Commitments and Contingencies_3
Commitments and Contingencies - Schedule of Future Minimum Payments Under Lease Agreements (Details) - USD ($) | Mar. 31, 2020 | Feb. 28, 2016 |
Total future lease payments | $ 3,200 | |
Total | $ 199,164 | |
Lease Agreements [Member] | ||
2020 (Remaining nine months) | 66,339 | |
2021 | 91,379 | |
2022 | 62,274 | |
Total future lease payments | 219,992 | |
Less imputed interest | 20,828 | |
Total | $ 199,164 |
Subsequent Events (Details Narr
Subsequent Events (Details Narrative) - USD ($) | Jun. 30, 2021 | Jun. 22, 2021 | May 20, 2021 | Mar. 10, 2021 | Dec. 31, 2020 | Nov. 30, 2020 | Jun. 30, 2018 | Jun. 30, 2021 | Apr. 30, 2021 | Mar. 31, 2021 | Feb. 28, 2021 | Jan. 31, 2021 | Nov. 30, 2020 | Oct. 31, 2020 | Sep. 30, 2020 | Aug. 31, 2020 | Jul. 31, 2020 | Jun. 30, 2020 | May 31, 2020 | Apr. 30, 2020 | Jan. 31, 2019 | May 31, 2017 | Mar. 31, 2020 | Mar. 31, 2019 | Jun. 30, 2021 | Jul. 31, 2021 | Dec. 31, 2019 | Feb. 28, 2019 | Dec. 31, 2018 | Apr. 30, 2014 |
Warrants, exercise price per share | $ 0.025 | |||||||||||||||||||||||||||||
Debt instrument accrued interest | $ 12,150 | |||||||||||||||||||||||||||||
Loss on settlement of debt | (22,000) | $ 57,253 | ||||||||||||||||||||||||||||
Settlement of Convertible Promissory Notes [Member] | ||||||||||||||||||||||||||||||
Debt instrument, face amount | $ 553,301 | $ 12,000 | ||||||||||||||||||||||||||||
Minimum [Member] | ||||||||||||||||||||||||||||||
Warrants, exercise price per share | $ 0.03 | $ 0.001 | ||||||||||||||||||||||||||||
Consultant Agreement [Member] | Restricted Stock [Member] | ||||||||||||||||||||||||||||||
Stock issued during period, shares, issued for services | 100,000,000 | |||||||||||||||||||||||||||||
Convertible Notes Payable [Member] | ||||||||||||||||||||||||||||||
Debt instrument, original discount | $ 11,172 | $ 22,344 | $ 5,000 | |||||||||||||||||||||||||||
Warrants, exercise price per share | $ 0.001 | |||||||||||||||||||||||||||||
Number of warrants | $ 8,147 | |||||||||||||||||||||||||||||
Convertible Notes Payable [Member] | Restatement of Promissory Notes [Member] | ||||||||||||||||||||||||||||||
Repayments of convertible debt | $ 75,900 | |||||||||||||||||||||||||||||
Convertible Notes Payable [Member] | Minimum [Member] | ||||||||||||||||||||||||||||||
Debt conversion price | $ 0.00030 | $ 0.00010 | ||||||||||||||||||||||||||||
Convertible Notes Payable [Member] | Note Agreement [Member] | ||||||||||||||||||||||||||||||
Debt instrument, face amount | $ 1,000,000 | |||||||||||||||||||||||||||||
Proceeds from loan | $ 112,799 | |||||||||||||||||||||||||||||
Convertible Notes Payable [Member] | Warrant [Member] | ||||||||||||||||||||||||||||||
Warrants, exercise price per share | $ 0.001 | |||||||||||||||||||||||||||||
Convertible Notes Payable [Member] | Unrelated Third Parties [Member] | ||||||||||||||||||||||||||||||
Debt instrument, original discount | 9,250 | |||||||||||||||||||||||||||||
Convertible Notes Payable [Member] | Third Party [Member] | Restated [Member] | ||||||||||||||||||||||||||||||
Debt instrument, face amount | $ 75,900 | |||||||||||||||||||||||||||||
Convertible Notes Payable [Member] | Unrelated Third Party [Member] | ||||||||||||||||||||||||||||||
Debt instrument, face amount | $ 12,629 | $ 12,629 | ||||||||||||||||||||||||||||
Debt instrument, interest rate | 8.00% | |||||||||||||||||||||||||||||
Debt instrument, expiration or maturity date | May 4, 2018 | |||||||||||||||||||||||||||||
Subsequent Event [Member] | Restatement of Promissory Notes [Member] | ||||||||||||||||||||||||||||||
Debt instrument, face amount | $ 166,926 | |||||||||||||||||||||||||||||
Debt instrument, due date | 2021-01 | |||||||||||||||||||||||||||||
Debt instrument, interest rate | 2.00% | |||||||||||||||||||||||||||||
Debt instrument accrued interest | $ 23,258 | |||||||||||||||||||||||||||||
Number of shares issued | 29,072,500 | |||||||||||||||||||||||||||||
Number of shares issued, value | $ 343,056 | |||||||||||||||||||||||||||||
Other income | 319,798 | |||||||||||||||||||||||||||||
Restated debt balance | 183,619 | |||||||||||||||||||||||||||||
Subsequent Event [Member] | Settlement of Convertible Promissory Notes [Member] | ||||||||||||||||||||||||||||||
Debt instrument, face amount | $ 8,500 | |||||||||||||||||||||||||||||
Debt instrument fair value | $ 15,200 | |||||||||||||||||||||||||||||
Debt instrument accrued interest | $ 166,168 | |||||||||||||||||||||||||||||
Number of shares issued | 2,000,000 | |||||||||||||||||||||||||||||
Number of shares issued, value | $ 4,000 | |||||||||||||||||||||||||||||
Repayment of debt | 4,500 | |||||||||||||||||||||||||||||
Loss on settlement of debt | 11,200 | |||||||||||||||||||||||||||||
Subsequent Event [Member] | Restated [Member] | Restatement of Promissory Notes [Member] | ||||||||||||||||||||||||||||||
Debt instrument, face amount | 166,926 | $ 148,225 | ||||||||||||||||||||||||||||
Debt instrument, original discount | $ 16,693 | |||||||||||||||||||||||||||||
Debt instrument, due date | 2021-08 | |||||||||||||||||||||||||||||
Debt instrument accrued interest | $ 18,701 | |||||||||||||||||||||||||||||
Subsequent Event [Member] | Unrelated Third Parties [Member] | Common Stock Issued for Default Payments [Member] | ||||||||||||||||||||||||||||||
Debt instrument, face amount | $ 26,950 | |||||||||||||||||||||||||||||
Debt instrument, original discount | $ 2,450 | |||||||||||||||||||||||||||||
Debt conversion price | $ 0.01 | |||||||||||||||||||||||||||||
Debt instrument, expiration or maturity date | Mar. 10, 2022 | |||||||||||||||||||||||||||||
Subsequent Event [Member] | Unrelated Third Parties [Member] | Convertible Note [Member] | ||||||||||||||||||||||||||||||
Debt instrument, face amount | $ 145,200 | |||||||||||||||||||||||||||||
Debt instrument, original discount | $ 13,200 | |||||||||||||||||||||||||||||
Debt conversion price | $ 0.01 | |||||||||||||||||||||||||||||
Debt instrument, expiration or maturity date | May 20, 2022 | |||||||||||||||||||||||||||||
Subsequent Event [Member] | Two Year Loan Agreement [Member] | Payroll Protection Program [Member] | ||||||||||||||||||||||||||||||
Proceeds from loan | $ 64,895 | |||||||||||||||||||||||||||||
Debt instrument, term | 24 months | |||||||||||||||||||||||||||||
Subsequent Event [Member] | Two Year Loan Agreement [Member] | Payroll Protection Program [Member] | ||||||||||||||||||||||||||||||
Debt instrument, interest rate | 1.00% | |||||||||||||||||||||||||||||
Subsequent Event [Member] | SBA Loan Agreement [Member] | Economic Injury Disaster Loan [Member] | ||||||||||||||||||||||||||||||
Debt instrument, face amount | $ 731 | $ 731 | ||||||||||||||||||||||||||||
Proceeds from loan | $ 150,000 | 150,000 | ||||||||||||||||||||||||||||
Advance loan received | $ 5,000 | $ 5,000 | ||||||||||||||||||||||||||||
Debt instrument, interest rate | 3.75% | 3.75% | ||||||||||||||||||||||||||||
Subsequent Event [Member] | Consultant Agreement [Member] | ||||||||||||||||||||||||||||||
Stock issued during period, shares, issued for services | 30,000,000 | |||||||||||||||||||||||||||||
Stock based compensation description | 5,000,000 of the shares were issued upon execution of the agreement and 5,000,000 shares will be issued every 30 days through November 2021. The compensation charge will be amortized over the term of the agreement. | |||||||||||||||||||||||||||||
Subsequent Event [Member] | Warrant [Member] | ||||||||||||||||||||||||||||||
Debt instrument, original discount | $ 7,500 | $ 7,500 | ||||||||||||||||||||||||||||
Warrants, exercise price per share | $ 0.002 | $ 0.002 | ||||||||||||||||||||||||||||
Number of warrants, granted | 71,875,000 | |||||||||||||||||||||||||||||
Number of warrants | $ 30,417 | $ 30,417 | ||||||||||||||||||||||||||||
Subsequent Event [Member] | Note Holder [Member] | Settlement of Convertible Promissory Notes [Member] | ||||||||||||||||||||||||||||||
Debt instrument, face amount | $ 11,000 | $ 22,000 | $ 22,000 | |||||||||||||||||||||||||||
Stock issued during period, restricted stock | 107,817,770 | 107,133,333 | ||||||||||||||||||||||||||||
Debt instrument accrued interest | $ 10,345 | $ 10,140 | ||||||||||||||||||||||||||||
Number of shares issued | 11,000,000 | |||||||||||||||||||||||||||||
Number of shares issued, value | $ 104,500 | |||||||||||||||||||||||||||||
Remaining debt sold | $ 467,319 | |||||||||||||||||||||||||||||
Repayment of debt | 6,000 | |||||||||||||||||||||||||||||
Loss on settlement of debt | 98,500 | |||||||||||||||||||||||||||||
Subsequent Event [Member] | Note Holder [Member] | Common Stock Issued for Default Payments [Member] | Restricted Stock [Member] | ||||||||||||||||||||||||||||||
Stock issued during period, restricted stock | 25,000,000 | 1,500,000 | 10,000,000 | 1,000,000 | ||||||||||||||||||||||||||
Stock issued during period, restricted stock value | $ 107,500 | $ 900 | $ 6,000 | $ 700 | ||||||||||||||||||||||||||
Repayments of convertible debt | $ 166,926 | 84,000 | 333,543 | 22,000 | ||||||||||||||||||||||||||
Subsequent Event [Member] | Note Holder [Member] | Repayments of Debt in Cash [Member] | Settlement of Convertible Promissory Notes [Member] | ||||||||||||||||||||||||||||||
Repayment of debt | $ 5,000 | |||||||||||||||||||||||||||||
Subsequent Event [Member] | Unrelated Third Party [Member] | Settlement of Convertible Promissory Notes [Member] | ||||||||||||||||||||||||||||||
Debt instrument accrued interest | 250,000 | |||||||||||||||||||||||||||||
Subsequent Event [Member] | Related Party [Member] | Settlement of a Related-Party Note [Member] | ||||||||||||||||||||||||||||||
Debt instrument, face amount | 14,400 | |||||||||||||||||||||||||||||
Debt instrument, original discount | $ 2,400 | |||||||||||||||||||||||||||||
Number of shares issued | 5,000,000 | |||||||||||||||||||||||||||||
Number of shares issued, value | $ 3,000 | |||||||||||||||||||||||||||||
Repayment of debt | $ 14,400 | |||||||||||||||||||||||||||||
Subsequent Event [Member] | Convertible Notes Payable [Member] | Minimum [Member] | ||||||||||||||||||||||||||||||
Debt conversion price | $ 0.0008 | $ 0.0008 | $ 0.0003 | $ 0.0008 | $ 0.0008 | |||||||||||||||||||||||||
Subsequent Event [Member] | Convertible Notes Payable [Member] | Unrelated Third Parties [Member] | ||||||||||||||||||||||||||||||
Debt instrument, face amount | $ 864,225 | $ 864,225 | $ 717,667 | $ 864,225 | $ 16,100 | |||||||||||||||||||||||||
Debt instrument, original discount | $ 112,725 | $ 112,725 | $ 93,609 | $ 112,725 | $ 2,100 | |||||||||||||||||||||||||
Debt conversion price | $ 0.002 | $ 0.002 | $ 0.002 | $ 0.002 | $ 0.002 | |||||||||||||||||||||||||
Subsequent Event [Member] | Convertible Notes Payable [Member] | Note Agreement [Member] | ||||||||||||||||||||||||||||||
Proceeds from loan | $ 128,937 | |||||||||||||||||||||||||||||
Stock issued during period, restricted stock | 240,350,000 | |||||||||||||||||||||||||||||
Stock issued during period, restricted stock value | $ 120,175 | |||||||||||||||||||||||||||||
Debt instrument fair value | $ 2,344,399 | $ 2,344,399 | 2,344,399 | |||||||||||||||||||||||||||
Subsequent Event [Member] | Convertible Notes Payable [Member] | Warrant [Member] | ||||||||||||||||||||||||||||||
Debt instrument, original discount | $ 29,481 | |||||||||||||||||||||||||||||
Warrants, exercise price per share | $ 0.001 | |||||||||||||||||||||||||||||
Subsequent Event [Member] | Convertible Notes Payable [Member] | Unrelated Third Parties [Member] | ||||||||||||||||||||||||||||||
Debt instrument, face amount | $ 16,500 | $ 38,500 | 20,900 | |||||||||||||||||||||||||||
Debt instrument, original discount | $ 1,650 | $ 7,550 | $ 1,900 | |||||||||||||||||||||||||||
Debt instrument, due date | 2021-04 | 2021-02 | ||||||||||||||||||||||||||||
Repayments of convertible debt | $ 19,500 | $ 19,500 | ||||||||||||||||||||||||||||
Subsequent Event [Member] | Convertible Notes Payable [Member] | Note Holder [Member] | ||||||||||||||||||||||||||||||
Debt instrument, face amount | 121,560 | 20,000 | $ 121,560 | $ 20,000 | 121,560 | |||||||||||||||||||||||||
Debt instrument, original discount | $ 9,200 | |||||||||||||||||||||||||||||
Debt instrument, due date | 2022-03 | 2021-01 | ||||||||||||||||||||||||||||
Debt conversion price | $ 0.0005 | $ 0.00052 | ||||||||||||||||||||||||||||
Stock issued during period, restricted stock | 240,350,000 | |||||||||||||||||||||||||||||
Stock issued during period, restricted stock value | $ 120,175 | |||||||||||||||||||||||||||||
Debt instrument fair value | $ 2,344,399 | $ 2,344,399 | $ 2,344,399 | |||||||||||||||||||||||||||
Subsequent Event [Member] | Convertible Notes Payable [Member] | Unrelated Third Parties One [Member] | ||||||||||||||||||||||||||||||
Debt instrument, face amount | $ 22,000 | |||||||||||||||||||||||||||||
Debt instrument, original discount | $ 2,000 | |||||||||||||||||||||||||||||
Subsequent Event [Member] | Convertible Notes Payable [Member] | Note Holder One [Member] | ||||||||||||||||||||||||||||||
Debt instrument, due date | 2021-08 | |||||||||||||||||||||||||||||
Debt conversion price | $ 0.0005 | |||||||||||||||||||||||||||||
Subsequent Event [Member] | Convertible Notes Payable [Member] | Unrelated Third Parties Two [Member] | ||||||||||||||||||||||||||||||
Debt instrument, face amount | $ 5,500 | |||||||||||||||||||||||||||||
Debt instrument, original discount | $ 500 | |||||||||||||||||||||||||||||
Subsequent Event [Member] | Convertible Notes Payable [Member] | Note Holder Two [Member] | ||||||||||||||||||||||||||||||
Debt instrument, due date | 2021-02 | |||||||||||||||||||||||||||||
Debt conversion price | $ 0.0005 | |||||||||||||||||||||||||||||
Subsequent Event [Member] | Convertible Notes Payable [Member] | Third Party [Member] | ||||||||||||||||||||||||||||||
Debt instrument, face amount | $ 55,900 | |||||||||||||||||||||||||||||
Debt instrument, due date | 2021-01 | |||||||||||||||||||||||||||||
Stock issued during period, restricted stock | 100,000,000 | |||||||||||||||||||||||||||||
Stock issued during period, restricted stock value | $ 20,000 | |||||||||||||||||||||||||||||
Subsequent Event [Member] | Convertible Notes Payable [Member] | Three Unrelated Third Parties [Member] | ||||||||||||||||||||||||||||||
Debt instrument, face amount | 208,800 | 208,800 | ||||||||||||||||||||||||||||
Debt instrument, original discount | $ 19,800 | $ 19,800 | ||||||||||||||||||||||||||||
Debt conversion price | $ 0.0005 | $ 0.0005 | ||||||||||||||||||||||||||||
Subsequent Event [Member] | Convertible Notes Payable [Member] | Three Unrelated Third Parties [Member] | Minimum [Member] | ||||||||||||||||||||||||||||||
Debt conversion price | $ 0.00022 | $ 0.00022 | ||||||||||||||||||||||||||||
Subsequent Event [Member] | Convertible Notes Payable [Member] | Unrelated Third Parties [Member] | ||||||||||||||||||||||||||||||
Debt instrument, face amount | $ 139,150 | $ 139,150 | ||||||||||||||||||||||||||||
Debt instrument, original discount | $ 12,650 | $ 12,650 | ||||||||||||||||||||||||||||
Debt conversion price | $ 0.00055 | $ 0.00055 | ||||||||||||||||||||||||||||
Subsequent Event [Member] | Two Convertible Notes Payable [Member] | Unrelated Third Parties [Member] | ||||||||||||||||||||||||||||||
Debt instrument, face amount | $ 57,500 | $ 57,500 | $ 57,500 | |||||||||||||||||||||||||||
Debt instrument, original discount | $ 7,500 | $ 7,500 | $ 7,500 | |||||||||||||||||||||||||||
Debt conversion price | $ 0.0008 | $ 0.0008 | $ 0.0008 |
Subsequent Events - Summary of
Subsequent Events - Summary of Warrants Issuance (Details) - USD ($) | 1 Months Ended | |||
Oct. 31, 2020 | Aug. 31, 2020 | Dec. 31, 2019 | Feb. 28, 2019 | |
Number of Warrants | 44,000,000 | 110,000,000 | ||
Fair Value of Warrants | $ 7,370 | $ 8,147 | ||
Month of Expiration | August, 2020 | August, 2019 | ||
Subsequent Event [Member] | Warrant [Member] | ||||
Number of Warrants | 39,930,000 | 92,100,000 | ||
Fair Value of Warrants | $ 8,633 | $ 20,848 | ||
Month of Expiration | October, 2022 | August, 2021 |
Subsequent Events - Schedule of
Subsequent Events - Schedule of Common Stock Issued for Conversion of Debt (Details) - USD ($) | Jun. 24, 2021 | Jun. 01, 2021 | Apr. 26, 2021 | Mar. 03, 2021 | Feb. 25, 2021 | Oct. 05, 2020 | Sep. 21, 2020 | Feb. 18, 2020 | Jan. 21, 2020 |
Number of shares converted | 250,000,000 | 250,000,000 | |||||||
Fair value of debt converted | $ 275,000 | $ 150,000 | |||||||
Subsequent Event [Member] | Note Holder [Member] | |||||||||
Number of shares converted | 2,500,000 | 5,700,000 | 27,070,000 | 67,380,000 | 137,700,000 | 107,817,770 | 107,133,333 | ||
Fair value of debt converted | $ 16,250 | $ 35,340 | $ 192,197 | $ 599,682 | $ 1,500,930 | $ 64,691 | $ 171,413 |